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Dolutegravir (DTG) is a potent human immunodeficiency virus type 1 (HIV-1)
integrase strand-transfer inhibitor (INSTI) with a high barrier to viral drug resistance.
However, opportunities to improve its profile abound. These include extending the drug’s
apparent half-life, increasing penetrance to “putative” viral reservoirs, and reducing
inherent toxicities. These highlight, in part, the need for long-acting, slow effective release
antiretroviral therapy (LASER ART) delivery schemes. A long-acting (LA) DTG was made
by synthesizing a hydrophobic and lipophilic prodrug encased with poloxamer (P407)
surfactant. This modified DTG (MDTG) reduced systemic metabolism and polarity,
increased lipophilicity and membrane permeability, improved encapsulation, and formed
stable nanoparticles upon formulation. MDTG was synthesized through esterification of
DTG with myristic acid. Poloxamer encasement was prepared for native and modified
DTG (NDTG and NMDTG, respectively) with thorough characterization. NMDTG was
characterized morphologically by uniform rod-shaped particles. It was taken up and
retained avidly in human monocyte-derived macrophages (MDM) for > 30 days with no
demonstrable cytotoxicity. Protection against viral infection was recorded for > 30 days
against HIV-1ADA challenge as determined by HIV-1 reverse transcriptase (RT) activity in

culture fluids and cell-based HIV-1p24 staining. Parallel native DTG responses were
operative for one day. Pharmacokinetics (PK) testing in mice showed that drug apparent
half-life was increased from 62 to 330 hours for NDTG and NMDTG, respectively, with
drug levels of the latter above the protein-adjusted 90% inhibitory concentration (PA-IC90)
of 64 ng/mL > 8 weeks following a single intramuscular (IM) dose. At day 28, NMDTG had
> 100-fold higher tissue drug levels than NDTG and were still demonstrable at day 56.
NMDTG protected humanized mice from parenteral challenge of HIV-1ADA for two weeks.
Further PK testing in three rhesus macaques demonstrated that a single IM injection of
NMDTG can provide plasma drug levels above the PA-IC90 for one month and can greatly
extend drug apparent half-life (467 h). Taken together, these results are a first-step
towards producing a potent, long-acting, slow-release DTG for the treatment and
prevention of HIV-1 in humans by affecting drug apparent half-life, cell and tissue drug
penetration, and antiretroviral potency.
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CHAPTER 1 – INTRODUCTION*†

1.1.

Introduction
Human immunodeficiency virus-1 (HIV-1) infects then depletes CD4+ T

lymphocytes resulting in immunodeficiency and host susceptibility to a range of
opportunistic infections and malignancies [1-3]. All have been reduced in severity and
cause as a result of global research efforts in disease pathogenesis, epidemiology, natural
history and most notably combination antiretroviral therapy (cART) [4-11]. The introduction
of cART allowed for effective suppression of HIV-1 replication within infected patients, and
resulted in a substantial reduction of morbidity and mortality in the infected population [12].
Antiretrovirals completely changed the clinical landscape of HIV-1 patients; instead of
unrestricted progression and certain death, HIV became a chronic but treatable disease,
with patients living decades beyond their initial infection. A significant global, political, and
social research effort has emerged to make antiretroviral therapy (ART) available
worldwide [13-15]. This and the newer advanced therapies are the standards of care [16];
all evolving from the initial discovery, more than 30 years ago, of HIV [17,18]. In rapid
succession the molecular structure, function, regulation, tropism, means of viral
persistence and potent therapies were discovered [19-21].
Aseptic meningitis is known to occur early after viral infection and is characterized
by nuchal rigidity, fever and altered mentation [22,23]. However, in most patients, the HIV-

*

Adapted with permission from Edagwa B, McMillan J, Sillman B, Gendelman HE: Long-acting
slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 1-11. (Copyright
Taylor & Francis).
†

Adapted with permission from Sillman B, Woldstad C, McMillan J, Gendelman HE:
Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol (2018)
152(21-40). (Copyright Elsevier).
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seroconversion reaction is subclinical and often passes unnoticed. Still patients may
present with a mild influenza-like illness and rarely a mononucleosis-like syndrome
[23,24]. A portion of these individuals will develop headaches, fever, myalgia, anorexia,
rash, and diarrhea within weeks of infection, known as “systemic acute retroviral
syndrome” [25-28]. The early stages of HIV infection can be classified into two groups: the
“acute phase” that is prior to the seroconversion, and the “early phase” that is the period
12 months post-seroconversion. The acute phase of viral infection is characterized by a
rapid HIV-mediated loss of memory CD4+CCR5+ T cells within the mucosal tissues, which
can potentially result in irreversible immune suppression [29-33]. During this acute phase,
high levels of viremia and viral shedding at mucosal sites occur. Genital and oral ulcers,
cancers, and coinfections with a range of sexually transmitted diseases that include
herpes simplex and hepatitis viruses, syphilis, and gonorrhea can manifest during the viral
seroconversion reaction [34-37].
The transition from the acute to chronic phase of infection is accompanied by
generation of HIV-1-specific adaptive immune responses [31,38,39]. Initially, HIV-specific
cytotoxic CD8+ T cell and humoral responses (for example, neutralizing antibodies)
function to reduce viral replication to a set-point level that is characteristic of chronic HIV
infection [40-45]. Although this is a robust initial immune response, it cannot eradicate viral
infection [38,46,47]. Continuous low-level or restricted infection of naïve CD4+ T cells and
MP evade immune surveillance. The persistence of these quiescent, but infected, cellular
reservoirs makes it difficult to eradicate the virus. In the early years of the pandemic, most
HIV patients were young and exhibited severe immune compromise; individuals had a
survival period of only a few years from the initial diagnosis with very few ever living to
experience old age [48].
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Prior to the advent of potent antiretroviral therapy, HIV infection was characterized
as an acute, systemic infection that rapidly led to immune suppression and cognitive
decline [49]. With the development of antiretroviral therapies, extended life expectancies
and a better quality of life for patients with AIDS have been achieved [50]. The decision to
start antiretroviral therapy used to be largely based on CD4+ T cell count thresholds,
although higher viral loads have been shown to increase the risk of disease progression.
However, in 2015, the World Health Organization (WHO) changed the current guidelines,
recommending that ART should be initiated in all adults living with HIV at any CD4 cell
count [51]. This was largely due to the findings of the Strategic Timing of Antiretroviral
Treatment (START) trial; finding a 57% reduction in serious AIDS-related, serious nonAIDS-related events and death from any cause for those who immediately began ART
compared to deferring ART until CD4 count declined to less than 350 cells/µL [52].
While ART has reduced disease morbidity and mortality it has thus far failed to
clear virus from anatomical reservoir sites and complications associated with infection are
still prevalent, as the virus is never wholly eliminated. Antiretroviral medicines fail to
completely eradicate the virus, in part because of a latent form of the virus that persists in
resting memory CD4+ T cells [53,54] and select viral mutations that result in viral
resistance to antiretroviral drugs (Johnson et al., 2005). Tissue reservoir sites, including
the central nervous system, gut-associated lymphoid tissue (GALT), lymph nodes and
spleen also persist. Thus, achieving virologic cure through antiretroviral drugs (ARVs)
currently remains a formidable and perhaps an improbable obstacle to overcome [55-57].
This is further complicated by limited access to ART seen commonly in resource-limited
countries, adverse drug side effects, viral mutation rates that have led to emergence of
resistant viral strains and poor patient compliance to lifelong therapy due to psychological,
physical and drug addictions [58-61].
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Viral reservoirs represent a potentially lifelong persistence of replicationcompetent forms of HIV-1, recovered from resting CD4+ T cells [53] and peripheral blood
monocytes [62], that cannot be suppressed by current antiretroviral treatments. Primary
and acquired antiretroviral resistance rates reflect the relative usage of different
antiretroviral drugs in the population, as well as the inherent genetic barrier to the
development of resistance associated with individual drugs. Data on antiretroviral
resistance rates, gleaned from the growing HIV-1-infected population treated with a
continuously increasing number of antiretroviral drugs and drug combinations, provide
insight to the relative ease by which HIV-1 escapes the selective pressure of chronic drug
exposure. Strains of HIV-1 that are resistant to reverse transcriptase and protease
inhibitors arise in the majority of treated patients who have either poor adherence to the
treatment regime or low plasma drug levels for other reasons [63]. Most importantly, virus
resistance to drugs heralds increased viral loads, immune suppression, and the onset of
neurological impairments associated with advanced viral infection [64]. The development
of novel adjunctive immunotherapies to use in combination with antiretroviral drugs
provide new therapeutic strategies to combat infection that will be better tolerated and
have a decreased potential for the emergence of viral resistance. New research will
continue to provide more options for such patients, with new treatments and potentially
vaccines on the horizon.
Taken together, the need for the development of reservoir targeted long acting
slow effective release (LASER) ART delivery platforms cannot be overstated. Parallel
efforts in academic laboratories and the pharmaceutical industry are directed towards
developing personalized drug delivery systems that can selectively target body areas
where virus hides in a latent, restricted or productive state. The inevitable outcome is to
maximize the therapeutic index, improve ARV compliance and maximize viral control [65-
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67]. The question, though, is how best to achieve such a goal. This has led, in measure,
to a reassessment of drug development. This can occur by modification of existing
compounds to affect improved drug encapsulation into delivery systems or to re-evaluate
drugs that were overlooked during prior evaluations. Indeed, the latter compounds could
be brought forward from new drug discovery efforts that have not moved ahead in
development due to their poor physicochemical properties such as limited oral absorption,
low dissolution at physiological pH and rapid clearance [68-70]. To overcome these
delivery barriers, drug delivery designs and dosage forms, delivery routes, nano- and
microcarrier systems such as liposomes, lipid nanoconstructs, polymeric nanoparticles,
dendrimers, and nanocapsules may be used to facilitate carriage of drugs and affect their
biodistribution and apparent half-life. Indeed, for example, nanomedicine-based drug
delivery systems are being developed with promising profiles that enable improved
targeting and imaging capacities and specifically target HIV reservoirs. Taken together,
the current chapter is more extensive than what is ongoing in our own laboratory and
highlights “all drug delivery platforms” that have already shown or have the potential to
improve therapeutic outcomes for HIV/AIDS now and in future years.
1.2.

Nanoparticle-mediated, sustained-release ART delivery
Delivery of therapeutic agents using solid lipid nanoparticles has received

considerable interest in recent years. This is owing to the abilities to introduce targeting
ligands, improve biocompatibility, limit drug degradation and reduce systemic toxicity.
Solid lipid nanoparticles comprise biocompatible lipids stabilized by emulsifiers. The use
of lipid nanoparticles to deliver multiple therapeutic agents in a single particle has drawn
increased interest in recent years. Packaging multiple ARVs into one particle is important
for targeting different stages of viral replication and reducing the risk of viral resistance. In
addition to facilitating residual viral clearance, co-delivery of multiple antiretroviral drugs
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could potentially enhance patient adherence. Most recently, multi-drug lipid nanoparticles
encapsulating the ARVs lopinavir (LPV), ritonavir (RTV) and tenofovir (PMPA) were
developed [71]. The lipid ARV nanoparticles were administered subcutaneously to rhesus
macaques at drug doses of 25, 14.3 and 17.1 mg/kg, respectively, and compared to native
drug treatments. Primates dosed with lipid nanoparticles exhibited extended and higher
drug concentrations in plasma and tissues. The three-drug lipid nanoparticle combinations
increased intracellular drug concentrations of LPV and RTV in the lymph nodes by 50-fold
compared to the native drug treatment group. Additionally, both plasma and intracellular
drug levels in the nanoparticle treatment group were sustained for 7 days, as opposed to
administration of native drugs, which were undetectable at day 2. These findings
demonstrated that multifunctional long acting ARV nanoparticles hold promise to
overcome inherent compliance limitations of the current drug regimens.
A major obstacle to the goal of HIV eradication lies in targeting latently infected
cells from a spectrum of tissue sites. While several therapeutic interventions are being
developed with the goal of targeting reservoirs that harbor latent virus none have delivered
enough cargo at long enough intervals with optimal efficacy to exert viral clearance
[72,73]. The directives include a broad number of direct and indirect measures to affect
the viral replication cycle. The ultimate end point is designed to eliminate infected resting
CD4+ T lymphocytes [74,75]. In this manner, a number of drugs were tested that would
affect viral clearance and potential elimination. For example, CD4+ T cell-activating agents
were investigated but proven unsuccessful in eliminating virus and preventing its rebound
as measured at two or three weeks affect ARV cessation. Ongoing research is focused
on generating slow release products that combine latency-breaking agents and
antiretroviral drugs in the same carrier. In a recent study, tenofovir was co-encapsulated
with the HIV-1 latency reversing agent vorinostat into magnetically guided layer-by-layer
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nanoparticles to allow for simultaneous activation and clearance of the virus [76]. The
ultra-small

magnetic

nanoparticles

were

synthesized

and

characterized

for

physicochemical properties, cytotoxicity, intracellular uptake, release and antiviral
responses using astrocytes and brain microvascular endothelial cells. In addition, the
effects of an external magnetic field on the transmigration ability and blood brain barrier
(BBB) integrity were investigated. Tenofovir-vorinostat nanoparticles demonstrated
antiretroviral efficacy over a period of five days after infection, an indication that the
external field facilitated intracellular accumulation of nanoparticles.
Delivery of ARV to the central nervous system (CNS) is critical for effective
treatment of HIV/AIDS patients but always challenging due to the limited permeability of
the BBB [77]. Recent years have seen advancements in the development of promising
nanotechnologies for delivery of antiretroviral drugs to the CNS [78]. Notably, amphiphilic
polymer coated iron oxide nanoparticles synthesized by solvothermal methods and
functionalized with the antiretroviral peptide enfuvirtide were shown to facilitate drug
carriage across the BBB [79].

The mechanism of nanoparticle transport across the

endothelial barrier was investigated using both in vitro and in vivo models demonstrating
intracellular distribution of enfuvirtide-modified iron oxide nanoparticles. Comparisons
were made against free peptide or non-modified iron oxide particle controls using confocal
microscopy methods. The results showed that coating the iron oxide nanoparticles with
enfuvirtide modified the amphiphilic polymer and markedly improved endothelial cell
permeation of the drug. The data showed up to 170% increases in permeation. Similarly,
increased fluorescence intensity was observed in brains of mice treated with
nanoformulated enfuvirtide iron oxide compared to free peptide or non-modified
nanoparticle treatment groups. The data, all together, showed peptide penetration of the
modified nanoparticles across endothelial cells with strong interactions between the
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polymer coating and cell membrane. This was followed by internalization and dissociation
of the nanocomplex in the brain parenchyma. These encouraging findings suggest that
amphiphilic polymer iron oxide nanoconstructs could potentially enhance CNS drug
delivery.
Nanosuspensions are aqueous suspensions containing poorly water-soluble drug
crystals and stabilizers [69,72,80]. One or several excipients and appropriate buffers are
used to prevent crystal growth or particle aggregation. Particle size reduction can be
achieved through high-pressure homogenization, wet milling or precipitation to generate
nanoparticles in the range of 50 to less than 1000 nm. Nanoparticles offer numerous
advantages that include high drug loading capacity, controllable size, charge and tunable
surfaces for targeting ligand conjugation and can be lyophilized for long term storage [8083]. Antiretroviral drugs could be nanoformulated to extend the drug apparent half-life and
for various routes of administration. Cabotegravir (CAB) is an integrase strand-transfer
inhibitor with high potency (IC50 of 0.22 nM), low aqueous solubility, and long half-life of
40 hours when delivered orally [84]. CAB-LAP is an aqueous, long-acting injectable
nanosuspension of CAB stabilized by polysorbate 20, polyethylene glycol 3350, and
mannitol with an apparent half-life ranging from 21 to 50 days after intramuscular (IM)
administration and is currently under clinical evaluation [85,86]. In a study by Andrews et
al., pharmacokinetics and efficacy of CAB-LAP for pre-exposure prophylaxis (PrEP)
against repeat high-dose intravaginal SHIV challenge was evaluated in female rhesus
macaques [87]. The study was conducted with eight female rhesus macaques that were
exposed to CAB-LAP at week 0 and four positive controls. The animals were then
chronically infected with SHIV162P3 at week 1 and monitored for viral loads. CAB-LAP
was found to protect the animals from infection, whereas viremia was detected at 2 weeks
after SHIV challenge in all control animals. The animals in the experimental treatment arm
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were given a boost of CAB-LAP at week 4 and further challenged with the virus at weeks
5 and 7. Interestingly, six out of eight animals in the CAB-LAP arm were protected against
three high-dose SHIV challenges, whereas all control animals showed infection after a
single challenge. These encouraging results highlight the potential of long acting injectable
nanosuspensions in the management of HIV.
The use of antiretroviral drugs for PrEP in high-risk populations has been shown
to be highly effective at preventing HIV transmission [88-91]. Current studies evaluated
long acting injectable medicines for PrEP that included raltegravir (RAL) nanosuspensions
prepared by milling and subsequent reconstitution in polyethylene glycol, polysorbate 80
and mannitol. Pharmacokinetic and biodistribution profiles of the drug were evaluated by
replicate formulations administered to BALB/c, NSG (NOD [non-obese diabetic]–scid
[severe combined immunodeficient] IL2Rgammanull; severely immunodeficient mice with
deficiencies in B, T, and functional NK cells allowing for humanization by engraftment of
human stem cells and/or tissues) and humanized bone marrow–liver–thymus (BLT) mice
and also in rhesus macaques [92]. Furthermore, in vivo assays were used to assess the
ability of the nanoformulated drug to protect humanized mice against vaginal virus
transmission and during acute infection. Plasma drug concentrations at two weeks after a
single injection of nanoformulated RAL at doses of 7.5 mg and 160 mg to BLT mice and
rhesus macaques, respectively, were equivalent to a twice-daily oral dose of 400 mg in
humans. Effective suppression of viral plasma RNA was achieved with a single dose of
nanoformulated RAL. A single subcutaneous dose of nanoformulated RAL protected BLT
mice from HIV infection following two high-dose vaginal challenges with virus at one week
and four weeks post administration of long acting nanoformulated RAL. The outcomes of
this study highlight the translational potential of long acting injectable antiretroviral drug
delivery systems for HIV prevention and treatment.
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Rilpivirine (RPV) is an FDA approved non-nucleoside reverse transcriptase
inhibitor (NNRTI) for use in HIV-1 infected naive patients in combination with other
antiretroviral agents. A long-acting nanosuspension of RPV, RPV LA, has been developed
by encapsulation of RPV in poloxamer 338 and manufactured by wet milling technology
and is under clinical investigation as a long acting injectable formulation [93]. Preclinical
studies have demonstrated sustained therapeutic concentration of RPV in plasma for up
to three months in dogs, two months in rats or three weeks in mice after a single dose of
RPV LA [93,94]. Others assessed the pharmacokinetics, safety and tolerability profiles of
RPV LA following single IM doses of 300 to 1200 mg in HIV seronegative volunteers [95].
RPV concentrations in plasma, cervico-vaginal fluid, rectal fluid and tissues from female
genital tract and male rectum were measured over 84 days after drug treatment. Results
from this study demonstrated that higher doses of nanoformulated RPV provide sustained
release and enhanced tissue biodistribution of the drug for up to 84 days. Higher RPV
concentrations corresponded to enhanced ex vivo inhibition of the virus replication in
infected cervico-genital tissues from participants. These encouraging clinical findings
suggest that long-acting ARVs could improve efficacy and adherence to PrEP treatments.
In another study, the pharmacokinetics, safety, and tolerability profiles of CAB and RPV
were assessed after repeated dosing of long-acting injectable formulations in healthy
subjects [96]. According to the study design, the subjects received oral doses of 30 mg/day
of CAB during the initial two weeks, followed by a seven-day wash out period prior to
administration of nanoformulated drugs. The subjects were then divided into four
treatment groups. The first group received 800 mg of CAB-LAP via intramuscular (IM)
injection followed by quarterly booster doses of 200 mg via subcutaneous (SC) injection.
The second group was dosed with 800 mg CAB-LAP via IM injection followed by quarterly
booster doses of 200 mg IM. The third group was administered 800 mg of CAB-LAP via
IM injection followed by quarterly booster doses of 400 mg IM. The fourth group received
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800 mg CAB-LAP IM followed by a booster IM dose of 800 mg 12 weeks later. Subjects
in the second and third groups also received IM doses of RPV LA at the third (1200 mg)
and fourth (900 or 600 mg) months. Spreen et al. noted that co-administration of CABLAP and RPV LA was well tolerated and sustained therapeutic plasma concentrations of
the two drugs were achieved. Clinical trial studies that are still in progress or have been
completed using CAB-LAP and/or RPV LA for PrEP or HIV-1 treatment are summarized
in Table 1.1 [97-99].
Alternative drug delivery systems are also being investigated. Dextran electrospan
microconfetti fibers loaded with the protease inhibitor saquinavir were synthesized from
acetylated dextran by grinding techniques to affect drug release kinetics [100]. The drug
loading capacities and properties of the fibers were compared against other polymers such
as poly lactic-co-glycolic acid and polycaprolactone. The results showed that the release
profile of saquinavir from the microconfetti formulations was dependent on the stability of
the polymer and drug concentration. A single subcutaneous administration of the dextran
microconfetti formulations at a dose of 80 mg/kg of saquinavir into mice sustained serum
and tissue drug concentrations for seven days. These encouraging data sets suggest
injectable microconfetti carriers could be used for delivery of other hydrophobic small
molecule drugs.
Additionally, biodegradable drug polymer implants are under development for
“ultra-long-acting” removable drug delivery. Such a system was developed with solid ARV
polymer gels to deliver the HIV-1 integrase inhibitor dolutegravir (DTG) for up to 9 months
at a dose of 250 mg/kg in mice [101]. The gel was made from a combination of polylacticco-glycolic acid and N-methyl-2-pyrrolidone in a solution of drug dissolved in an organic
solvent. Upon subcutaneous injection of the DTG-containing solution, the polymer will
solidify at the injection site to form the implant. However, there is the potential for dumping
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a large amount of drug from the biodegradable polymers. As the implant is biodegradable,
any need for surgical removal is a challenge especially at longer times after insertion.
Moreover, the organic solvent used to dissolve the hydrophobic ARVs, and the high
viscosity of the gel, could cause injection site reactions. These limitations could be
overcome by refillable devices that do not require repeated surgical insertion or removal
[102].
1.3.

Targeted delivery
Active targeting is accomplished by attachment of specific molecules, peptides or

proteins on the surface of the delivery system, thereby maximizing binding and
interactions with receptors expressed on target cells or tissues [83,103,104]. The choice
of the appropriate ligand is based on its specificity, stability, availability and selectivity on
the target cells or tissues. Targeted co-delivery of ARVs to infected CD4+ T cells and
macrophages has great potential in the management of HIV-1 infection. Ramana et al.
developed anti-CD4 modified liposomes loaded with nevirapine and saquinavir and
evaluated them for cellular uptake and antiretroviral responses in Jurkat T cell lines [105].
The liposomes were prepared by thin film hydration and covalently linked to anti-CD4
antibody via thiol-maleimide chemistry. Entrapment and association of each drug within
the lipid layers of the liposome was influenced by physicochemical properties of each
compound, with the aqueous core associated hydrophilic saquinavir exhibiting a slower
release rate compared to the hydrophobic nevirapine localized in the surrounding lipid
bilayers. The dual drug loaded anti-CD4 modified liposomes exhibited enhanced drug
uptake and improved antiretroviral efficacy compared to equimolar concentrations of
native drugs. These in vitro experiments demonstrated that active targeting of CD4+ T cells
could facilitate intracellular localization and improve the efficacy of antiretroviral drugs.
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Harnessing macrophage transport properties for drug delivery can improve clinical
drug responses. Indeed, cell-based nanocarriers have been developed for not only cancer
chemotherapy but also a wide range of microbial infections [104,106,107]. Cell targeted
nanomedicines may offer several advantages over conventional drug delivery methods
including enhanced efficacy, reduced side effects, increased drug stability and effective
subcellular targeting [79,108,109]. To facilitate macrophage targeting, our laboratory
developed injectable ART nanoformulations and evaluated drug delivery to macrophage
subcellular compartments and tissues, and assessed the pharmacokinetic drug profile [8082,108-112]. Rapid uptake and accumulation of hydrophobic drug nanocrystals in
endosomal compartments was observed, without notable changes in cell morphology, cell
viability or cell function [113,114] (Fig. 1.1). Folic acid (FA) is the ligand for the folate
receptor (FOLR) which is expressed on the surface of macrophages and can facilitate
increased drug uptake through receptor-mediated endocytosis [115]. FA was covalently
conjugated onto poloxamer 407 and used to manufacture nanosuspensions of the
protease inhibitor atazanavir, (ATV; FA-nanoATV) by high-pressure homogenization
[108,116,117]. These results showed that in comparison with non-targeted formulation,
FA-nanoATV increased macrophage ATV uptake and retention 2-fold, and provided
robust anti-HIV efficacy in the Rab 5, 7 and 11 endosomal compartments.
Pharmacokinetic evaluation in mice showed that a single IM injection of FA-nanoATV
enhanced ATV concentration in plasma nearly 10-fold at 14 days post-injection.
Furthermore, ATV concentration in lymph nodes increased nearly 4-fold and in liver and
kidneys by up to 5-fold over non-targeted nanoformulations at day 14 [108]. Antiretroviral
efficacy of ritonavir boosted ATV nanoformulations administered to NSG mice
reconstituted with human peripheral blood lymphocytes then infected with HIV-1ADA
showed viral suppression by measures of viral load, number of HIV-1p24+ cells in lymphoid
tissue and polymerase chain reaction for viral RNA [116]. These results demonstrated the
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role played by FA targeting of ARV nanoparticles in improving the pharmacokinetics and
pharmacodynamics of long acting drug nanoformulations.
1.4.

Prodrugs and drug polymer conjugates
Yet another approach that has been utilized to improve physiochemical properties

of drug molecules rests in prodrug design. Prodrugs themselves do not possess intrinsic
biological activity but are capable of generating biologically active drugs during their
metabolism [118,119]. Typically, prodrug strategies are aimed at conferring improved
properties to the parent drug that would enhance delivery across physiological barriers or
allow for encapsulation into delivery systems [120]. The success of this approach relies
upon cleavage of the chemical linkage between the active parent drug and the derivatizing
moiety in order to elicit a pharmacological effect [119]. The nature of the chemical linkage
is therefore an important consideration. Also, prodrugs should not elicit toxicity. Various
ester, carbamate and amide prodrugs can be hydrolyzed by carboxyesterases [119].
Even though prodrug strategies have been successfully utilized in many
medicines, only a few prodrug products for HIV therapy have been marketed to date. Only
fosamprenavir and tenofovir disoproxil fumarate anti-HIV prodrugs have been approved
by the FDA [121,122]. The majority of pharmaceutical research into the utility of long acting
prodrug injectable formulations has been in the area of antipsychotics. Several long acting
antipsychotic parenteral agents are clinically available [123]. These formulations include
prolixin decanoate sesame oil formulation, marketed by Bristol Myers Squibb as a
biweekly injectable, and paliperidone palmitate nanosuspension, marketed by Janssen as
a monthly injectable for acute treatment of schizophrenia [124-126]. Prodrug based drug
delivery systems are an attractive strategy for the development of long acting formulations
that might significantly simplify the frequency of dosing ART; potentially lowering dosing
schedules from 365 dosing days per year to 12 or fewer with monthly or longer dosing
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strategies [122]. Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of
combination antiretroviral therapy in the treatment of HIV infection [127]. However, these
drugs have short half-lives and often require daily or twice daily dosing to maintain
therapeutic drug levels. The hydrophilic nature of NRTIs pose further challenges to the
development of long acting nanoformulations. A recent article described the synthesis of
a library of lamivudine (3TC) prodrug polymer conjugates and evaluated their drug release
kinetics through measurement of glutathione-mediated release of 3TC and in vitro antiviral
efficacy against HIV entry and polymerase activity [128]. The copolymers were assembled
by reversible addition-fragmentation chain transfer (RAFT) polymerization reactions. The
release of 3TC from the polymer occurred over 5 and 10 hours for non-sulfonated and
sulfonated polymers, respectively. The polymer conjugates studied by others exhibit
potent kinase independent reverse transcriptase inhibition as well as activity against
DNA−DNA polymerase. Prior works had shown sulfonic acid polymers to exhibit
antiretroviral responses through interaction with the viral glycoprotein gp120 preventing
cell membrane fusion [129-131]. These in vitro data demonstrate that surfactants that
exhibit anti-HIV activity could be used in the design of multimodal carriers that might
protect cells from invasion by the virus.
To overcome limitations of short acting NRTIs, our laboratory recently developed
slow release products of 3TC (NM3TC) and abacavir (ABC; NMABC) extending their
apparent half-lives from hours to weeks [81,112]. Myristoylated prodrugs of 3TC (M3TC)
and ABC (MABC) were produced then encapsulated into poloxamer 407 excipients. Both
non-targeted and FA-modified poloxamer nanoformulations of MABC and M3TC were
manufactured by high-pressure homogenization to generate particles that were
characterized by stable physical properties. The prodrug nanosuspensions were then
tested to assess uptake and retention of MABC and M3TC particles in macrophages. An
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up to 2.5-fold increase was observed in ABC uptake of FA decorated nanoformulated
MABC (FA-NMABC) when compared to replicate undecorated formulation. Blocking the
FA receptor decreased FA-NMABC uptake. Increased MABC retention in macrophages
over 15 days was seen for FA-NMABC. Similarly, uptake of FA decorated nanoformulated
3TC (FA-NM3TC) increased over 24 hours. This mirrored improved antiretroviral efficacy
of the nanoformulated drugs. FA-NMABC and FA-NM3TC suppressed HIV-1 reverse
transcriptase (RT) activity for up to 15 days. To determine whether improved
hydrophobicity and encapsulation of MABC and M3TC into nanoformulations would
translate into sustained plasma drug levels in vivo, mice were treated IM with native drugs
or nanoformulated prodrugs (equivalent to 50 mg/kg active drug). Mice were maintained
on folate deficient diet prior to drug administration to reduce circulating folate levels. Blood
levels of ABC were detectable over 14 days following treatment with NMABC. Similarly,
3TC levels were detectable over 10 days following treatment with NM3TC. At day 14, the
plasma 3TC level for FA-NM3TC was 22.7± 12.5 ng/mL and that of NM3TC was at the
limit of quantitation. Similarly, 3TC levels in the liver, spleen and lymph nodes were greater
than 2-fold higher for the FA-NM3TC treated group compared to the NM3TC group. These
exciting results demonstrate that short acting drugs can be converted into slow release
products and packaged into macrophages to improve bioavailability and pharmacokinetics
of the parent drugs. Such delivery systems bring the drugs to sites of active viral replication
and therefore hold great potential for clinical application.
1.5.

Anti-inflammatory and neuroprotective agents affecting combination ART
depots
Efforts have been made to improve ART delivery across the BBB. However, recent

studies have also demonstrated that improved CNS penetrance could itself contribute to
neurocognitive dysfunction [132-134]. In an effort to overcome such limitations,
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neuroprotective agents are being developed to protect vulnerable neurons against
cellular, viral, and drug neurotoxins [135]. To date, none of the neuroprotective clinical
trials have moved forward to clinical practice [136]. In a phase I clinical study the mixedlineage kinase 3 (MLK3) inhibitor CEP-1347 given together with ritonavir boosted
atazanavir (ATV/r) enhanced plasma drug levels and extended the antiretroviral drug
apparent half-life in infected patients [137]. However, one compound in particular has been
shown to affect nanoART efficacy while at the same time providing anti-inflammatory and
neuroprotective activities. This compound is the next generation MLK3 inhibitor, URMC099, that has been shown to play a key role in attenuating pro-inflammatory responses
and has been shown to have neuroprotective properties [138]. This MLK3 inhibitor,
URMC-099, is brain-penetrant and has been shown to facilitate nanoART depots in HIV1 tissue reservoirs. While URMC-099 alone had no antiretroviral effect its coadministration with nanoATV demonstrated enhanced suppression of HIV-1 [139].
Combination of URMC-099 and nanoATV potentiated antiretroviral responses compared
to the ARV treatment alone. The antiretroviral responses paralleled increased drug levels
in early, late and recycling endosomes. Interestingly, such endosomal compartments are
known to be major subcellular HIV reservoirs [113,140,141]. Recently, it was
demonstrated that the mechanisms underlying URMC-099 enhancement of antiretroviral
responses were based on stimulation of autophagy and later sequestration of drug
particles into autophagosomes [142].
1.6.

Excision and elimination of HIV proviral DNA
Previously developed "shock and kill" strategies have failed to eradicate latent viral

reservoirs [143]. Such past strategies are not efficient nor are they specifically acting
leading to eradication failures and cell and tissue toxicities. Currently, efforts are underway
to combine strategies to improve drug delivery to viral reservoirs by novel decorated
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nanomedicines by enabling molecular discoveries that remove proviral DNA from infected
T cells and in coordinate efforts prevent ongoing viral infection by mutating CCR5. To such
ends, short palindromic repeat (CRISPR)-associated protein-9 nuclease (Cas9) systems
were developed for HIV-1 proviral excision in order to eliminate latent provirus [144,145].
The means to deliver this cargo to lymphoid tissues such as GALT and lymph nodes as
well as the CNS and specifically to CD4+ T cells and macrophages is being sought
[104,105,108,117]. Certainly, the needs to develop novel polymer and medicinal chemistry
approaches for optimal manufacture of receptor-targeted nanoformulated Cas9 is of
utmost importance and inevitably to use such approaches to efficiency use such
formulations in reducing provirus DNA in infected cell reservoirs of virus.
1.7.

Dolutegravir (DTG)
The integration of HIV-1 viral DNA with the host cell’s genome is a critical step in

the viral lifecycle, as the inserted DNA serves as the template for new HIV-1 RNA
production within the infected cell. This reaction is catalyzed by the HIV-1 encoded
enzyme integrase, and successful inhibition of integrase has been clinically shown to be
an effective therapy for managing HIV-1 infection and disease progression. The
integration reaction can be classified into two steps: the 3’-processing, in which a site
specific endonucleolytic cleavage reaction removes two nucleotides from each end of the
viral DNA strand, and strand transfer, where the now-processed HIV-1 DNA is physically
transferred into host genome [146].
There are currently four FDA approved integrase inhibitors: raltegravir (2007),
dolutegravir (2013), elvitegravir (2014), and bictegravir (2018). DTG, an approved secondgeneration integrase strand transfer inhibitor (INSTI), demonstrates potent activity against
HIV-1 with a 90% protein-adjusted inhibitory concentration (PA-IC90) of 64 ng/mL, better
tolerability, fewer adverse drug reactions, fewer drug interactions, and higher genetic
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barrier to resistance mutations [84]. As such, DTG is unique amongst other compounds
by its robust resistance profile and measured efficacy in inhibiting HIV-1 growth. Current
recommendations suggest dosing 50 mg of DTG orally either once or twice per day,
depending on known resistance mutations to previous generation integrase inhibitors.
Additionally, DTG is widely used in high-income countries and is being recommended by
the World Health Organization (WHO) as the preferred first-line HIV regimen, as well as a
preferred treatment by the U.S. Department of Health and Human Services Panel on
Antiretroviral Guidelines for Adults and Adolescents, among many others. A breakthrough
pricing agreement has also been announced which will accelerate the availability of the
first affordable, generic, single-pill HIV treatment regimen containing DTG to public sector
purchasers in low- and middle-income countries at around $75 per person per year and is
expected to accelerate treatment rollout globally. Forecasts suggest that approximately
15 million people will be taking DTG-based regimens by 2021, progressively replacing
efavirenz (EFV)-containing regimens [147]. Taken together, DTG is an extremely
attractive candidate for further modification and improvement, and, ultimately,
transformation into LASER ART with potentially enormous implications and application.
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1.9.

Figures

Figure 1. 1. Macrophage uptake and storage of nanoformulated DTG prodrug
crystals.
(A) Transmission electron microscopy (TEM) images of a human monocyte-derived
macrophage (MDM) displaying eccentric nuclei, abundant cytoplasm, well-develop
endoplasmic reticulum, lysosomes, and Golgi with intracytoplasmic vacuoles and a villus
plasma membrane (magnified 6,500x). (B) Higher magnification (30,333x) of highlighted
area from panel A. (C) Replicate human MDM treated for two hours with 100 µM
nanoformulated DTG prodrug displays abundant intracellular vesicles within the
cytoplasm rich with drug nanocrystals (magnified 6,500x). (D) Higher magnification
(30,333x) of highlighted region from panel C.
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1.10.

Tables

Table 1. 1. Clinical trial data sets for CAB-LAP and RPV LA for HIV-1 prevention and
treatment.
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CHAPTER 2 – ADJUNCTIVE THERAPY AFFECTING DEPOTS OF
NANOFOMULATED DOLUTEGRAVIR IN VIVO‡

2.1.

Introduction
The next generation, brain-penetrant, mixed-lineage kinase 3 (MLK3) inhibitor,

URMC-099, has been shown to affect nanoART efficacy while at the same time providing
anti-inflammatory and neuroprotective activities. Inhibition of MLK3 activation in HIV
infection has also been shown to have neuroprotective properties [138] and has been
shown to play a key role in attenuating pro-inflammatory responses. URMC-099 has been
shown to facilitate nanoART depots in HIV-1 tissue reservoirs. While URMC-099 alone
had no antiretroviral effect its co-administration with nanoATV demonstrated enhanced
suppression of HIV-1 [139]. Combination of URMC-099 and nanoART potentiated
antiretroviral responses compared to the ARV treatment alone. The antiretroviral
responses paralleled increased drug levels in early, late and recycling endosomes.
Interestingly, such endosomal compartments are known to be major subcellular HIV
reservoirs [113,140,141]. However, the mechanisms for how the MLK-3 inhibitor restricts
viral growth were not known. Here we demonstrate that URMC-099 enhancement of
antiretroviral responses is due to stimulation of autophagy leading to subsequent
sequestration of drug particles into autophagosomes. The work, in toto, is a notable step
forward towards development of sustained release ARVs for human use.

‡

Adapted with permission from Gnanadhas DP, Dash PK, Sillman B, Bade AN, Lin Z, Palandri DL,
Gautam N, Alnouti Y, Gelbard HA, McMillan J, Mosley RL et al: Autophagy facilitates
macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest
(2017) 127(3):857-873. (Copyright American Society for Clinical Investigation).
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2.2.

Methods

2.2.1. Transmission electron microscopy
Drug loaded MDM were analyzed by transmission electron microscopy (TEM) after
treatment for 8 hours. Cells were washed, scraped into PBS, pelleted at 3,000 rpm for 8
min at room temperature, and fixed in a solution of 2% glutaraldehyde, 2%
paraformaldehyde in 0.1 M Sorenson’s phosphate buffer (pH 6.2). A drop of the fixed cell
suspension was placed on a formvar/silicon monoxide 200 mesh copper grid, allowed to
settle for 2 min, and the excess solution wicked off and allowed to dry. A drop of NanoVan
vanadium negative stain was placed on the grid for 1 min, then wicked away and allowed
to dry. Grids were examined on a FEI Tecnai G2 Spirit TWIN transmission electron
microscope (Hillsboro, OR) operated at 80 kV, and images were acquired digitally with an
AMT digital imaging system (Woburn, MA).
2.2.2. Reagents
Poloxamer 407 (P407) was purchased from Sigma-Aldrich (St. Louis, MO). Cell
culture grade water (endotoxin-free), acetonitrile (ACN), methanol, and KH2PO4 were
purchased from Fisher Scientific (Hampton, NH). Antibodies included LC3B (NB100,
Novus Biologicals, Minneapolis, MN), SQSTM1/P62 (PM045, MBL International, Woburn,
MA), and BECN1 (H300, Santa-Cruz Biotechnology, Dallas, Texas). Dolutegravir (DTG)
was a generous gift from ViiV Healthcare (Brentford, Middlesex, United Kingdom). URMC099 (MW: 421.54 g/mol) was synthesized by Califla Bio Inc. (San Diego, CA).
2.2.3. Preparation of nanoformulated antiretroviral drugs
Nanoformulations of DTG were prepared by high-pressure homogenization
(Avestin EmulsiFlex-C3, Avestin Inc., Ottawa, ON, Canada) [80,108]. For nanoDTG
preparations, DTG (5% w/v) and P407 (0.3% w/v) were combined in HPLC-grade water
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at a ratio of 100:6. The suspensions were homogenized at 20,000 psi until the desired
particle size (300-400 nm) was achieved. nanoDTG was used without further purification.
Particle size, polydispersity, and surface charge (zeta potential) were determined by
dynamic light scattering using a Malvern Zetasizer Nano ZS (Malvern Instruments Inc.,
Westborough, MA). Particle size, zeta potential, and polydispersity index (PDI) were 315
± 30, -13 ± 0.10 and 0.21 ± 0.02 for DTG nanoformulations. DTG loading was determined
by HPLC using a Phenomenex Kinetix C18 column (5 µm; 150 x 4.6 mm) with a mobile
phase of 65% 50 mM KH2PO4, pH 3.2 / 35% acetonitrile at a flow rate of 1.0 mL/min and
254 nm detection. DTG was quantitated by comparison of peak areas to those of known
standards (0.05-50 µg/mL in methanol).
2.2.4. Pharmacokinetics (PK) evaluations
Male Balb/cJ mice were injected intramuscularly (IM) with nanoDTG at 45 mg/kg,
with or without daily IP injections of URMC-099 at 10 mg/kg/day or equivalent vehicle
(poly(ethylene glycol)400:DMSO (8:1) mixture). Plasma was collected 1, 3, 7, 14, 21 and
28 days after nanoDTG treatment. Animals were sacrificed, and tissues (liver, spleen,
lymph nodes) were collected on days 14 and 28. DTG in plasma and tissues was
determined by UPLC-MS/MS.
2.2.5. Plasma and tissue dolutegravir quantification
DTG in plasma and tissues was determined by UPLC-MS/MS for which DTG from
plasma (25 μL) and tissues (100 mg) was extracted using 1 mL acetonitrile. Then, 10 μL
internal standard (IS; 1000 ng/mL SN-38) was added to each sample, and the samples
were vortexed, and then centrifuged at 17,000 x g for 10 min. Supernatants were dried
using a Savant Speed Vacuum (ThermoFisher Scientific), and reconstituted in 100 μL of
50% acetonitrile in Optima grade water. Standard solutions of DTG (0.2-2000 ng/mL) were
prepared by extracting 25 μL of blank plasma from control mice into 1 mL of acetonitrile,
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and adding 10 μL of IS and various concentrations of DTG. Chromatographic separation
of 10 μL of sample was achieved on an ACQUITY UPLC BEH Shield RP18 column (1.7
μm, 2.1 mm x 100 mm) using a 7- min gradient of mobile phase A (7.5 mM ammonium
formate in water, adjusted to pH 3 with formic acid) and mobile phase B (100% acetonitrile)
at a flow rate of 0.25 mL/min. The initial mobile phase conditions of 65% A were held for
3.5 min, decreased to 5% A over 1.5 min, held at 5% A for 1.5 min, then increased to 65%
A over 0.5 min, and held for 1 min. Drug was detected in the ESI positive mode with a
cone voltage of 10 V, and a collision energy of 25 V. The MRM transition used for DTG
was 420.08 > 277.12., and for SN-38, was 393.07 > 264.10. Spectra were analyzed and
quantified by MassLynx software version 4.1. In all cases, ratios of analyte to IS peak
areas were quantified.
2.2.6. Autophagy pathways measurements
Autophagy gene expression was analyzed using real time qPCR. RNA was
isolated from tissues using TRIzol (Applied Biosystems, ThermoFisher Scientific) as per
the manufacturer’s protocol. Residual DNA was removed using the TURBO DNA-free kit
(ThermoFisher Scientific). The isolated RNA (2 µg) was reverse transcribed to cDNA using
a Verso reverse transcription cDNA synthesis kit (ThermoFisher Scientific) as per the
manufacturer's instructions. TaqMan probes (ThermoFisher Scientific; Table 2.1) and realtime PCR master mix (Applied Biosystems) were used for real-time PCR (StepOne Plus,
Applied Biosystems) as per the manufacturer’s instructions. All samples were amplified in
triplicates, and data was normalized to actin cDNA. Liver and spleen homogenates were
also analyzed for autophagy markers by Western blot assays.
2.2.7. Statistical analyses
Data were analyzed using GraphPad Prism 6.0 software (GraphPad Software Inc,
La Jolla, CA) and Microsoft Excel. For comparison of two groups, Mann-Whitney test or
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one-tailed Student’s t-test were used. Multiple pairwise comparisons were corrected for
false discovery rate by the Benjamini-Hochberg procedure. Significant differences were
determined at P < 0.05.
2.2.8. Study approval
All animal studies were performed in compliance with UNMC institutional policies
and the National Institutes of Health guidelines for laboratory animal housing and care,
and were approved by the Institutional Animal Care and Use Committee of UNMC.

2.3.

Results
In rodents, URMC-099 activation of autophagy led to 50-fold increases in the

apparent half-life of the viral integrase inhibitor dolutegravir (DTG). DTG was used to
understand the role of autophagy and nanoART in vivo. Mice injected with a single IM
dose of 45 mg/kg nanoformulated DTG (nanoDTG) with or without daily IP injections of 10
mg/kg URMC-099 showed no adverse effects on body weight or health of the mice (Fig.
2.1A). Increased plasma DTG levels were observed in URMC-099-treated mice beginning
at day 14, and by day 28 there was a 52.3 ± 5.7-fold increase in the plasma drug level
compared to animals treated with nanoDTG alone (Fig. 2.2A). Similar increases in DTG
levels in spleen, liver and lymph nodes were achieved with URMC-099 treatment (Fig.
2.2B). At early time points, day 1 and day 3 after nanoDTG administration, drug levels in
both plasma and tissues were not significantly increased with URMC-099 and the
autophagy proteins were also not affected with URMC-099 at these time points suggesting
a delayed response (Fig. 2.1B-C).
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Real time qPCR from spleen and liver tissues showed a significant increase in tfeb
levels in URMC-099-treated mice which in turn promoted higher expression of the
autophagy genes map1lc3b, becn1 and sqstm1 (Fig. 2.2C–F). Western blot analyses
confirmed parallel induction of autophagy proteins in spleen and liver at 14 and 28 days
of URMC-099 treatment (Fig. 2.2G-H and Fig. 2.3A–E).

2.4.

Discussion
The needs for long-acting ART to meet the challenges of HIV/AIDS regimen

adherence are immediate. Notably, the secondary gains by reductions in drug dosages
and improved viral reservoir penetration are likely even more significant in the era of viral
eradication. To such ends, the means to facilitate drug depots and enhance vesicular
trafficking of ARV nanoparticles and its sequestration in endosomal compartments is
significant. The development of adjunctive drugs, such as URMC-099, to extend ART
actions by harnessing a natural cellular process, such as autophagy, to facilitate drug
depots is novel.
Autophagosomes play a vital role in HIV-1 biogenesis [148,149]. In macrophages,
autophagy is stimulated by HIV-1 through TLR8 signaling that occurs at early stages of
infection, while during chronic infection, autophagy is inhibited. The process is regulated,
in part, by the HIV-1 Nef protein [150] where HIV-1 inhibits autophagosome maturation to
evade its own destruction by lysosomal degradation [149]. URMC-099 activation of
autophagy can overcome HIV-1 mediated inhibition of autophagy. Thus, a dual
antiretroviral response is seen; one through intracellular degradation of virus and the other
by sustaining ARV particles that preclude new infections.
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These data support the notion that URMC-099 induced changes in endosomal
trafficking that affects known intracellular ARV particle accumulations [139]. Macrophages
play a key role in HIV-1 pathogenesis by forming viral reservoirs and selectively clearing
HIV-1 infected CD4+ T lymphocytes [151,152]. As nanoART is also taken up by
macrophages, increased retention, sustained release, and improved cellular viability by
activation of autophagy can facilitate anti-HIV treatment outcomes. As our animal studies
demonstrate that autophagy is induced in tissue macrophages and that combinations of
nanoformulated DTG and URMC-099 improve PK profiles, such treatment combinations
could serve to further reduce HIV disease morbidities. In summary, we have shown that
induction of autophagy leads to the retention and sustained release of nanoformulated
ARVs. Our results, for the first time, lend credence to the idea that induction of autophagy
by URMC-099 treatment activate a unique pathway that facilitates the biodistribution and
half-life of long-acting nanoART. As autophagosomes intersect with the HIV-1 lifecycle,
storage of the nanoformulated ARVs in intracellular compartments may further facilitate
HIV-1 disposal by harnessing intracellular events that contain viral growth.
Together, these results show that autophagy induction by URMC-099 enhanced
ARVs apparent half-life in vivo. Since autophagosomes are used for HIV-1 assembly and
maturation, URMC-099 induced autophagy could be harnessed to facilitate viral
clearance, improve cell health and facilitate accumulation and retention of ARV
nanoparticles at viral action sites. In conclusion, the demonstration that URMC-099 has
the potential to reduce the dosage and frequency of ARV administration and enhance
antiretroviral activities, supports the immediate development of this and like agents
towards the realization that sustained release products can be placed in the arsenal of
existing and effective anti-HIV medicines.
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2.5.

Figures

Figure 2. 1. URMC-099 and nanoDTG treatment in mice.
Mice were injected with single dose of 45 mg/kg nanoformulated dolutegravir
(nanoDTG) IM and treated with or without daily URMC-099 (10 mg/kg) IP injections. (A)
Every week mice weights were recorded for day 14 group mice (D14) and day 28 group
mice (D28). D14 mice were sacrificed on day 14 and D28 on day 28 for further analysis.
6 mice per group. (B) Drug (DTG) measurements in liver, spleen and lymph nodes in mice
treated with or without URMC-099 (10 mg/kg/daily) sacrificed at day 1 and day 3 after
nanoDTG administration (single dose of 45 mg/kg). 4 mice per group. (C) Liver and spleen
from mice from B were analyzed for autophagy proteins by Western blot. Each column
represents one mouse.
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Figure 2. 2. URMC-099 nanoART parenteral co-administration sustains plasma DTG
levels.
Mice were injected with single dose of 45 mg/kg nanoformulated dolutegravir
(nanoDTG) IM, and treated with or without daily IP injections of URMC-099 (10 mg/kg)
injection. (A) At different days blood was collected, and plasma DTG concentration was
determined by UPLC-MS/MS. (B) At day 14 (D14) and 28 (D28) mice were sacrificed, and
DTG level was quantified in different tissues by UPLC-MS/MS. (C–F) At day 14 (D14) and
day 28 (D28), total RNA was isolated from spleen and liver tissues, and real time qPCR
was performed for different genes. Values represents mean ± SEM. * P ≤ 0.05, ** P ≤
0.01, Mann–Whitney U test. 6 mice per group. (G,H) At day 14 and day 28, spleen and
liver tissues were collected, and total tissue lysate was analyzed for different autophagy
markers by Western blot. Each lane is representative of 5 animals drawn from each of the
groups. Multiple comparisons were corrected for false discovery rate by BenjaminiHochberg procedure. Six mice were assessed per group.
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Figure 2. 3. URMC-099 induces autophagy in nanoDTG injected mice.
(A-E) Quantification of Western blots performed for (A) BECN1 (B) SQSTM1 (C)
LC3BI and (D) LC3BII with liver tissue lysates from mice injected with single dose of 45
mg/kg nanoDTG IM and treated with or without daily URMC-099 (10 mg/kg) IP injections
and (E) represents LC3BII/LC3BI ratios from different groups. N=5 mice per group and
each dot represents a mouse. ns, not significant, * P ≤ 0.05, ** P ≤ 0.01, Mann–Whitney
U test.
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2.6.

Tables

Table 2. 1. Primer/probes for qRT-PCR.
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CHAPTER 3 – CREATION OF A LONG-ACTING
NANOFORMULATED DOLUTEGRAVIR§

3.1.

Introduction
Antiretroviral therapy (ART) has changed what was once a life-endangering human

immunodeficiency virus type one (HIV-1) infection to a chronic manageable disease.
Rapid immune suppression, opportunistic infections and malignancies were attenuated by
antiretroviral drug (ARV) therapy [3,153]. Patients adhering to defined ART regimens can
lead a fully productive life, experience limited infection-related morbidities and prevent
what was once a rapid inevitable death [50]. However, treatment advancements have
come at some cost. These include toxicities, adherence failures, costly regimens and
common viral mutations linked to specific resistance patterns [154]. A means to combat
each can be realized through drug regimen adherence facilitated by long-acting slow
effective release antiretroviral therapy (LASER ART) [155] as defined by slow drug
dissolution, enhanced lipophilicity, improved bioavailability and limited off-target toxicities.
Such changes in drug formulation affect the frequency of drug administration. Reductions
in disease co-morbidities follow the maintenance of effective antiretroviral drug
concentrations in blood, body fluids, and tissue viral reservoir tissues for months or longer
[156]. The end result is improved treatment outcomes.

§

Adapted from Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, Su H,
Kanmogne GD, Poluektova LY, Gorantla S, McMillan J et al: Creation of a long-acting
nanoformulated dolutegravir. Nat Commun (2018) 9(1):443. To view a copy of the
Creative
Commons
Attribution
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International
License,
visit
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While such a directive is attractive, not all ARVs can easily be transformed into
long-acting medicines. Drug solubility, dissolution, metabolism, protein-binding, and
excretion rates are not uniform amongst each drug; and each influence the ARV’s half-life
and biodistribution profile [69,70]. Long-acting medicines depend upon maintenance of
plasma drug concentrations, which are linked to depot formation and dissociation within
the reticuloendothelial system. Such changes in drug depot formation and dissociation,
referred to by the term apparent half-life, distinguish it from the drug’s intrinsic half-life.
Whether a medicine can be found with significant antiretroviral efficacy, limited resistance
patterns and high tolerability for conversion into a long-acting compound also remain
uncertain. While ARVs have been developed with long-acting properties based on their
solubility and protein-binding capacities, none are currently used clinically and only a few
(long-acting injectable cabotegravir and rilpivirine) are in clinical trials [156]. For these, the
drug formulations require larger injection volumes which can lead to injection site
reactions. Adjusted dosing intervals are also required when interpatient pharmacokinetic
(PK) profiles come operative [157-159]. To these ends, our laboratory developed a
process to transform standard daily or twice-daily ARVs into hydrophobic and lipophilic
drug nanocrystals to extend apparent half-life by altering drug solubility and metabolic
patterns [112]. Chemical modification and polymer coating techniques were used to
convert ARV’s into LASER ART.
In the current study, alteration of the DTG chemical structure is made through
myristoylation of the native compound to create a water-insoluble prodrug, termed MDTG,
with commensurate crystal formation. When the drug crystals are packaged into a
nanoparticle, MDTG is rapidly taken up by human monocyte-derived macrophages
(MDM), retained for a prolonged period inside the cells, and slowly released. MDTG
undergoes rapid bioconversion to the parent drug in the presence of esterases contained
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in biological fluids to yield a pharmacologically active product [160]. Such chemical and
biological outcomes improve antiretroviral activities up to 30-fold. Our data provide
evidence that DTG conversion into a long-acting, slow release formulation is readily
achievable. As such, the drug-encased nanoparticles could be employed as a first-step
measure to improve regimen adherence, limit adverse reactions by maximizing drug
loading and reducing excipient usage. Such improved treatment measures can also
minimize drug fatigue and facilitate drug penetrance into viral reservoirs.

3.2.

Methods

3.2.1. Reagents
DTG was a generous gift from ViiV Healthcare (Research Triangle Park, NC).
Pyridine, dimethylformamide (DMF), N,N-diisopropylethylamine (DIEA), myristoyl
chloride, poloxamer 407 (P407), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)

buffer,

ciprofloxacin,

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide (MTT), dimethyl sulfoxide (DMSO), paraformaldehyde (PFA), and 3,3’diaminobenzidine (DAB) were purchased from Sigma-Aldrich (St. Louis, MO). Diethyl
ether, cell culture grade water (endotoxin-free), gentamicin, acetonitrile (ACN), methanol,
KH2PO4, bovine serum albumin (BSA), and Triton X-100 were purchased from Fisher
Scientific (Hampton, NH). Monoclonal mouse anti-human HIV-1p24 (clone Kal-1),
monoclonal mouse anti-human leukocyte antigen (HLA-DP/DQ/DR; clone CR3/43), and
the polymer-based HRP-conjugated anti-mouse EnVision+ secondary were purchased
from Dako (Carpinteria, CA). Heat-inactivated pooled human serum was purchased from
Innovative Biologics (Herndon, VA). Dulbecco’s Modification of Eagle’s Medium (DMEM)
was purchased from Corning Life Sciences (Tewksbury, MA).
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3.2.2. MDTG synthesis and characterization
A lipophilic and hydrophobic modified DTG prodrug (called MDTG) was
synthesized through myristoylation of the parent drug hydroxyl group. Initially, DTG was
dried by co-evaporation from anhydrous pyridine then resuspended in anhydrous DMF
and cooled to 0 °C under argon. 2-equivalents DIEA were used to deprotonate the 7hydroxyl group of DTG, which was then immediately reacted with 2 equivalents myristoyl
chloride for 24 hours. The resultant product was purified by silica gel column
chromatography using an initial mobile phase of 4: 1 ethyl acetate: hexanes for 12
fractions, then 9: 1 ethyl acetate: hexanes for the remainder. Once purified, fractions
containing the UV active prodrug were dried and precipitated from diethyl ether. The
precipitate was collected by centrifugation at 3,500 rpm for 15 min and dried under
vacuum, while the supernatant was discarded. MDTG was synthesized at a final drug yield
of 82.8%. Proton nuclear magnetic resonance (1H NMR), carbon nuclear magnetic
resonance (13C NMR) and Fourier-transform infrared (FTIR) spectroscopy, positive
electrospray ionization mass spectroscopy (ESI-MS), and powder X-ray diffraction (XRD)
were used to characterize the structure of MDTG. NMR was performed on a Bruker
Avance-III HD (Billerica, MA) operating at 500 MHz, a magnetic field strength of 11.7
Tesla. MDTG 1H NMR spectrum specifics: (500 MHz, CDCl3) δ 10.20 (s, 1H), 8.45 (s, 1H),
7.35 (dd, J = 15.0, 8.2 Hz, 1H), 6.83 (app. dd, J = 19.1, 9.3 Hz, 1H), 5.26 (br. s, 1H), 4.855.01 (m, 1H), 4.62 (br. s, 1H), 4.30 (app. d, J = 12 Hz, 2H), 4.17 (dd, J = 13.3, 5.9 Hz 1H),
4.0 (app. d, J = 6.3 Hz, 1H), 2.73 (t, J = 7.6 Hz, 2H), 2.17 (td, J = 14.5, 7.2 Hz, 1H), 1.80
(app. t, J = 7.5 Hz, 2H), 1.51-1.61 (m, 2H), 1.40-1.49 (m, 2H), 1.36 (d, J = 7.0 Hz, 3H),
1.26 (br. s, 20H), 0.90 (t, J = 6.6 Hz, 3H). 13C NMR spectrum specifics: (125 MHz, CDCl3)

δ 171.9, 171.1, 163.3, 163.1, 161.6, 161.1, 159.6, 130.6, 130.5, 129.2, 121.3,
121.2, 119.5, 111.2, 111.1, 103.9, 103.7, 103.5, 76.1, 53.1, 36.5, 33.8, 31.9,
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29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 24.4, 22.6, 15.8, 14.1. ESI-MS specifics
(m/z): calculated for C34H45F2N3O6, 629.33 (100%), 630.33 (36.8%), 631.33 (3.9%);

found, 630.30. FTIR was performed on a PerkinElmer universal attenuated total
reflectance (UATR) Spectrum Two (Waltham, MA). XRD was performed in the 2θ range
of 2-70° using a PANalytical Empyrean diffractometer (Westborough, MA) with Cu-K%
radiation (1.5418 Å) at 40 kV and 45 mA and a solid state PIXcel3D detector
(Westborough, MA) at a rate of 0.033°/s with a diffracted beam monochromator. The
aqueous solubility of DTG and MDTG was evaluated by adding excess drug to water at
room temperature then mixing it overnight. Samples were spun at 14,000 rpm for 10 min
to pellet any insoluble drug. Solubilized drug in the supernatant was extracted in methanol
and measured using a Waters ACQUITY ultra-performance liquid chromatography
(UPLC) H-Class System with TUV detector and Empower 3 software (Milford, MA). For
DTG and MDTG quantitation, drug extracts were separated on a Phenomenex Kinetex 5
μm C18 column (150 × 4.6 mm) (Torrance, CA) using either 65% 50 mM KH2PO4, pH
3.2/35% ACN (DTG) or 90% ACN/10% water (MDTG) with a flow rate of 1.0 mL/min and
detected at 254 and 230 nm, respectively. Drug content was quantitated by comparison
of peak area to those of known standards (0.05 - 50 µg/mL). Ex vivo cleavage kinetics of
MDTG was assessed in mouse whole blood. Ten µL of 500 ng/mL spiking solution (50
ng/mL final drug concentration) was spiked into 100 µL blood, blood diluted 10X in PBS,
blood that was added to acetonitrile (ACN), or blood spiked with an esterase inhibitor
cocktail [20 mg/mL sodium fluoride (NaF) and 6 mg/mL ethylenediaminetetraacetic acid
(EDTA) with 100 µM phenylmethylsulfonyl fluoride (PMSF)] and incubated at room
temperature. At collection time points 1 mL ACN was added to stop any enzymatic activity.
For initial time points, ACN was first added to blood before spiking solution. Samples were
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then dried and analyzed for MDTG levels by UPLC tandem mass spectrometry (UPLCMS/MS; see below).
3.2.3. Nanoparticle synthesis and characterization
DTG and MDTG nanoparticles (NDTG and NMDTG, respectively) were formulated
on an Avestin EmulsiFlex-C3 high-pressure homogenizer (Ottawa, ON, Canada) using
P407 to encase the drug crystals. For NDTG, P407 (0.06% w/v) was first dissolved in
endotoxin-free water at pH 7.0. Drug (1% w/v) was then added at 100: 6 drug: polymer
ratio and mixed to form a pre-suspension. For NMDTG, P407 (0.1% w/v) was first
dissolved in 10 mM HEPES buffer, pH 7.8. Next, drug (1% w/v) was added at 10: 1 drug:
polymer ratio and mixed to form a pre-suspension. For both, high-pressure
homogenization (~20,000 psi) was then used to generate final homogenous drug
nanosuspensions of approximately 250-350 nm. Particle size, polydispersity index (PDI),
and zeta potential were determined by dynamic light scattering (DLS) using a Malvern
Nano-ZS (Worcestershire, UK) [82]. Particle release kinetics were determined for the
original undiluted nanoformulation batches and 10-fold diluted batches with the respective
buffers used for manufacture. Diluted and undiluted nanoformulations were incubated
over 7 days and 70 days, respectively, at 4 °C. Ten µL aliquots were collected into 990 µL
of 4% BSA in PBS at various time points. Samples were further diluted to 2 µg/mL with
the same 4% BSA solution, and 10 µL was withdrawn for total drug concentration analysis.
The remaining solution was centrifuged at 10,000 x g for 10 min. After centrifugation, 50
µL aliquots of supernatant were collected in 250 µL of methanol for released drug
concentration analysis. All samples were analyzed by LC-MS/MS for total and released
drug concentrations.
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3.2.4. In vitro monocyte-derived macrophage assays
Human monocytes were obtained by leukapheresis from HIV-1/2 and hepatitis B
seronegative donors, and then purified by counter-current centrifugal elutriation [161].
Human monocytes were plated in a 12-well plate at a density of 1.0 × 106 cells per well
using DMEM supplemented with 10% heat-inactivated pooled human serum, 1%
glutamine, 10 µg/mL ciprofloxacin, and 50 µg/mL gentamicin. Cells were maintained at 37
°C in a 5% CO2 incubator. After 7 days of differentiation in the presence of 1000 U/mL
recombinant human macrophage colony stimulating factor (MCSF), MDM were treated
with 100 μM DTG, MDTG, NDTG, or NMDTG. Native drugs were added in DMSO (0.1%
v/v). Uptake of drug was assessed by measurements of intracellular drug concentrations
at 2, 4, 8, 12, 16, or 24 hours after treatment [82]. For drug retention studies, cells were
treated for 8 hours then washed with PBS and maintained with half-media changes every
other day until collection at days 1, 5, 10, 15, 20, and 30. For both studies, adherent MDM
were washed with PBS, then scraped into PBS, and counted at indicated time points using
an Invitrogen Countess Automated Cell Counter (Carlsbad, CA). Cells were pelleted by
centrifugation at 3,000 rpm for 8 min at 4 °C. Cell pellets were briefly sonicated in 200 μL
methanol to extract drug and centrifuged at 14,000 rpm for 10 min at 4 °C to pellet cell
debris. DTG and MDTG drug content was determined by UPLC-UV/Vis as described
above. Release was assessed by collecting culture media after 4-hours of drug treatment
on days 1, 3, 5, 7, 10, 12, and 14. After collection, 150 μL of media was added to 1 mL of
HPLC-grade methanol and vortexed. Samples were centrifuged at 14,000 rpm for 10 min
at 4 °C. Supernatants were dried using a ThermoScientific Savant Speed Vacuum
(Waltham, MA), extracted drug resuspended in 150 µL HPLC-grade methanol, and drug
content was determined by UPLC-UV/Vis. To assess cell viability, MTT assay was
performed. Briefly, MDM were seeded on 96-well plates at a density of 80.0 x 105 cells
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per well and treated with various concentrations (1 - 500 μM) of NDTG or NMDTG for 6 or
24 hours. After drug treatment, cells were washed and incubated with 100 μL/well of MTT
solution (5 mg/mL) for 45 min at 37 °C. After incubation MTT was removed, and 200
μL/well of DMSO was added and mixed thoroughly. Absorbance was measured at 490
nm on a Molecular Devices SpectraMax M3 plate reader with SoftMax Pro 6.2 software
(Sunnyvale, CA). ROS species were measured in MDMs using a DCFDA cellular ROS
detection assay kit as per the manufacturer’s instructions (Abcam, Cambridge, MA).
Briefly, MDMs were seeded on black, clear-bottom 96-well plates at a density of 80.0 x
105 cells per well. Cells were then incubated for 45 min in 1X Buffer (supplied with the kit)
containing 25 µM DCFDA at 37 °C, then washed with 1X Buffer. Cells were treated with
DTG, MDTG, NDTG, or NMDTG at 100 and 400 μM for 2 hours, and DCF production was
measured by fluorescence spectroscopy with excitation and emission wavelengths of 485
and 535 nm, respectively. LDH cytotoxicity assay was performed in MDMs using an LDH
assay kit as per the manufacturer’s instructions (Abcam, Cambridge, MA). Briefly, MDMs
were seeded on white, clear-bottom 96-well plates at a density of 80.0 x 105 cells per well.
Cells were then treated with DTG, MDTG, NDTG, or NMDTG at 100 and 400 μM
concentrations for 24 hours. Five µL of media from each well was then mixed with 95 μL
of the reaction mixture (supplied with the kit), followed by measurement of fluorescence
at excitation and emission wavelengths of 535 and 587 nm, respectively. Phagocytic
activity was assessed in MDMs using the VybrantTM phagocytosis assay kit as per the
manufacturer’s instructions (Invitrogen, Carlsbad, CA) [114]. Briefly, MDMs seeded on 96well plates at a density of 80.0 x 105 cells per well were treated with NDTG or NMDTG
over a range of concentrations (10 - 500 μM) for 8-hours. Cells were then washed with
PBS and incubated for 2 hours with fluorescently labeled E. coli particles (supplied with
the kit) at 37 °C. Unbound particles were removed by aspiration, followed by quenching of

45
extracellular E. coli with trypan blue for 1 min, and fluorescence measurement at excitation
and emission wavelengths of 480 and 520 nm, respectively.
3.2.5. Scanning and transmission electron microscopy
Nanoparticle morphology was analyzed by scanning electron microscopy (SEM).
Briefly, nanosuspensions were air dried onto a glass coverslip mounted on an SEM
sample stub and sputter coated with approximately 50 nm of gold/palladium alloy.
Samples were examined using a FEI Quanta 200 scanning electron microscope
(Hillsboro, OR) operated at 5.0 kV. Drug loaded MDM were analyzed by transmission
electron microscopy (TEM) after treatment for 8 hours. Cells were washed, scraped into
PBS, pelleted at 3,000 rpm for 8 min at room temperature, and fixed in a solution of 2%
glutaraldehyde, 2% paraformaldehyde in 0.1 M Sorenson’s phosphate buffer (pH 6.2). A
drop of the fixed cell suspension was placed on a formvar/silicon monoxide 200 mesh
copper grid, allowed to settle for 2 min, and the excess solution wicked off and allowed to
dry. A drop of NanoVan vanadium negative stain was placed on the grid for 1 min, then
wicked away and allowed to dry. Grids were examined on a FEI Tecnai G2 Spirit TWIN
transmission electron microscope (Hillsboro, OR) operated at 80 kV, and images were
acquired digitally with an AMT digital imaging system (Woburn, MA).
3.2.6. Antiretroviral activities
Antiretroviral efficacy was determined by measurements of HIV reverse
transcriptase (RT) activity. For IC50 determination, MDM were exposed to various
concentrations (0.01 - 1,000 nM) of DTG or MDTG for 1 hour followed by challenge with
HIV-1ADA [161] at a multiplicity of infection (MOI) of 0.1 infectious particles per cell for 4
hours. Following viral challenge, cells were washed and incubated with the same
concentration of drug used before infection for an additional 10 days in culture. Culture
fluids were collected on day 10 for the measurement of RT activity as previously described
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[80,162,163]. To assess antiretroviral efficacy, MDM were treated with 100 μM DTG,
MDTG, NDTG, or NMDTG as described above for 8 hours. After treatment, cells were
washed with PBS and cultured with fresh media, with half-media exchanges every other
day. At 0, 4, 12 hours, and 1, 5, 10, 15, 20, 25, or 30 days after treatment, cells were
challenged with HIV-1ADA at a MOI of 0.1 infectious particles per cell for 16 hours. After
viral infection, the cells were cultured an additional 10 days with half-media exchanges
every other day. Culture fluids were collected for measurement of RT activity as previously
described [80,162,163]. Cells were fixed with 4% PFA and expression of HIV-1p24 antigen
was determined by immunocytochemistry.
3.2.7. Effect of macrophage-released DTG on T cell infection
Human MDM were treated with 100 μM NDTG or NMDTG for 4 hours, as described
above. Following 4-hour treatment, cells were washed and fresh media was applied for 24
hours. Conditioned medium, containing drug released from MDM during this 24-hour
period, was collected and used to assess antiretroviral activity in human peripheral blood
lymphocytes (PBLs). Freshly elutriated PBLs were stimulated with 10 μg/mL mitogen
phytohemagluttinin (PHA) and 20 U/mL interleukin-2 (IL-2) for 2-3 days. PBLs were then
infected with HIV-1MN at a MOI of 0.1 for 8 hours in the presence of conditioned media
from drug-treated MDM. Cells were washed and cultured with fresh media. PBLs were
replenished every three days to replace any dead and/or dying cells due to HIV-1 infection.
At days 9, 12, 15, 18, 21, and 24 after viral challenge, culture fluids were collected for the
measurement of RT activity as previously described [80,162,163].
3.2.8. Immunocytochemistry
For immunocytochemistry, cells were washed with PBS and fixed with 4% PFA at
room temperature for 15 min, followed by an additional washing with PBS. The cells were
treated with a blocking/permeabilizing solution (1% Triton X-100, 10% BSA in PBS) and
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incubated with mouse monoclonal antibody to HIV-1p24 (1:100) for 16 hours at 4 °C. Cells
were washed with PBS, and polymer-based HRP-conjugated anti-mouse secondary was
added for 30 min at room temperature. Cells were then washed with PBS and developed
with DAB. Nuclei were counterstained with Mayer’s hematoxylin, and cells were visualized
with a 20x objective on a Nikon Eclipse E800 microscope (Melville, NY) with Nuance EX
multispectral imaging system (PerkinElmer, Hopkinton, MA) [82].
3.2.9. Statistics
For all studies, data were analyzed using GraphPad Prism 7.0 software (La Jolla,
CA) and presented as the mean ± the standard error of the mean (SEM). Experiments
were performed using a minimum of three biologically distinct replicates. Sample sizes
were not based on power analyses. For comparisons of two groups, Student’s t test (twotailed) was used. HIV-1 RT activity and HIV-1p24 staining were analyzed by one-way
ANOVA with Bonferroni correction for multiple-comparisons. For studies with multiple time
points, two-way factorial ANOVA and Bonferroni’s post-hoc tests for multiple comparisons
were performed. Extreme outliers beyond the 99% confidence interval of the mean and 3fold greater than the SEM were excluded. Significant differences were determined at P <
0.05.

3.3.

Results

3.3.1. Synthesis and characterization of MDTG
A fourteen-carbon fatty-acid modified DTG prodrug (MDTG) was synthesized by
esterification of the 7-hydroxyl group of DTG with myristic acid with a final yield of 82.8%
(Fig. 3.1a). The chemical structure of MDTG was thoroughly characterized by proton
nuclear magnetic resonance (1H NMR), carbon nuclear magnetic resonance (13C NMR)
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and Fourier-transform infrared (FTIR) spectroscopy, positive electrospray ionization mass
spectroscopy (ESI-MS), and powder X-ray diffraction (XRD). 1H NMR spectral analysis
demonstrated the loss of the phenol proton peak at 12.5 ppm in the DTG spectrum (Fig.
3.2a). This was accompanied by chemical shifts at 0.9 ppm and 1.26 ppm for MDTG,
representing the 10 (CH3R) and 20 (RCH2R) protons of the aliphatic fatty-acid chain.
Chemical shifts at 2.73 ppm and 1.8 ppm correspond to protons at the Cα and Cβ positions
of the aliphatic ester (COOR) alkyl chain (Fig. 3.2b). 13C NMR spectral analysis of MDTG
shows all 34 carbon atoms present on the modified drug (Fig. 3.2c). ESI-MS analysis
shows the exact mass of MDTG to be 629.33 (100%), with daughter ion peaks at 630.33
(36.8%) and 631.33 (3.9%) (Fig. 3.2d). Additionally, strong absorption bands at 2915 cm1

and 2850 cm-1 in the FTIR spectrum of MDTG correspond to asymmetric and symmetric

methyl C-H stretches of the myristoyl alkyl group. Absorption bands at 1795 cm-1 and 1750
cm-1 in the spectra of myristoyl chloride and MDTG correspond to carbonyl C=O stretching
of the acyl chloride and ester functional groups, respectively (Fig. 3.1b). XRD confirmed
the crystalline forms of both DTG and MDTG, displaying unique diffraction patterns
indicating different atomic arrangements within the crystal lattice of each compound (Fig.
3.1c). Aqueous solubility and IC50 were compared for both DTG and MDTG. MDTG
exhibited an 8.7-fold decrease in aqueous solubility compared to DTG, confirming the
expected enhanced hydrophobicity from the fatty acid conjugate (Fig. 3.1d). Kinetics of
MDTG cleavage were assessed in whole blood. After 60 min, 79.9% of MDTG was
cleaved while 88.7% was hydrolyzed in blood diluted ten-fold. By comparison, 15.2% of
MDTG was hydrolyzed in blood spiked with an esterase inhibitor and 21.9% was cleaved
after acetonitrile (ACN) addition. This changed little over a 300 min observation period
(Fig. 3.5e). HIV-1 reverse transcriptase (RT) activity determined that the IC50 of MDTG
was not statistically different from DTG (62.5 and 56.7 nM, respectively; P = 0.8397) (Fig.
3.1e), confirming that antiretroviral activity of DTG was not altered following modification.
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3.3.2. Nanoformulation stability and release kinetics
Poloxamer 407 (P407) nanoformulations were prepared using direct synthesis by
high-pressure homogenization. Encapsulation efficiencies of NMDTG and NDTG were
82.2 ± 4.4% and 66.2 ± 1.0%, respectively (data not shown). Formulation stability was
determined over 134 days at both 4 °C and 25 °C (Fig. 3.3a-c). Particle size, polydispersity
index (PDI), and zeta potential for all formulations were determined by dynamic light
scattering (DLS). The size (Fig. 3.3a), PDI (Fig. 3.3b), and zeta potential (Fig. 3.3c) of
NMDTG were 234 ± 2 nm, 0.23 ± 0.02, and -21.6 ± 0.3 mV at day 0, respectively, and
remained stable at 4 °C over 134 days (363 ± 4 nm, 0.23 ± 0.01, and -12.1 ± 0.2 mV at
day 134). However, NMDTG was less stable at 25 °C, showing differences of 70 nm and
10.0 mV in size and zeta potential at day 134 from day 0, respectively, with no change in
PDI. NDTG particles (368 ± 6 nm at day 0) were larger than NMDTG particles, but
remained stable over the entire 134 days at both 4 °C and 25 °C (398 - 434 nm, 0.22 0.25, and 20.6 - 25.7 mV at day 134). Particle release kinetics were assessed for the
original, neat, undiluted formulations (Fig. 3.3d) to test for stability of manufactured LASER
ART, as well as after 10-fold dilution (Fig. 3.3e) to test the stability of dosing solutions. For
the neat, as well as diluted NDTG, there was a burst release of approximately 80% at time
zero, and the entire DTG content was released by day 70 from the neat formulation. Only
an additional 5% was released from the diluted NDTG by day 7. In contrast, for NMDTG,
the burst release was only 3.5% and 23% of NMDTG content at day zero for the neat and
diluted NMDTG, respectively. No further release of MDTG from the neat formulation was
observed over 70 days; whereas, only an additional 5% was released from the diluted
formulation over 7 days. In all incubations, mass balance analyses showed that 100% of
the drug was recovered.
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3.3.3. Nanoparticle characterization
Scanning electron microscopy (SEM) was used to assess particle morphology
(Fig. 3.4a, b). NMDTG particles (Fig. 3.4b; magnification = 30,000x) showed uniform,
dominant rod-shaped morphologies, while NDTG particles (Fig. 3.4a; magnification =
20,000x) were of heterogeneous size and shape and consisted of both cuboidal- and rodshaped morphologies. The former are known to be more amenable for MDM uptake
[80,164]. NMDTG was taken up avidly by MDM and intracellular concentrations increased
over a 24-hour test period (Fig. 3.4c). At 24 hours, the intracellular drug concentration was
74.3 µg/106 cells for NMDTG, 185-fold higher than NDTG (0.40 µg/106 cells) after
exposure to an equimolar concentration of DTG. Native MDTG also displayed significantly
higher uptake in MDM than either native DTG or NDTG (P < 0.0001); however, cellular
drug levels reached a maximum at 4 hours (16.7 µg/106 cells). Neither native DTG nor
NDTG achieved more than 1.0 µg/106 cells over 24 hours. NMDTG was also retained
within MDM for up to 30 days (31 ng/106 cells) (Fig. 3.4d). Native DTG and NDTG were at
undetectable levels at 24 hours (< 0.1 µg/106 cells). DTG, MDTG, and NDTG all showed
rapid release from MDM into the surrounding media (Fig. 3.4e). However, NMDTG
displayed a sustained, slow-release profile that reached a maximum at post drug
treatment day 5 and continued to day 14. No MDTG was detected with either MDTG or
NMDTG treatments, indicating MDTG rapidly hydrolyzes to DTG. Together, these data
indicate that NMDTG possesses long-acting and slow-release potential. Even with such
high intracellular drug levels, NMDTG showed no toxicity to MDM as determined by 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays after 6 and 24
hours of drug treatment (Fig. 3.5a and Fig. 3.4f, respectively). Only 24-hour treatment of
NDTG at the highest concentration (500 µM) showed reduced cell viability of 44.4%.
NMDTG also showed no toxicity as determined by lactate dehydrogenase (LDH) released
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into media after 24 hours of drug treatment at 100 or 400 μM concentrations in MDM. By
contrast, 400 µM DTG or NDTG treatment showed changes in cell vitality (Fig. 3.5c).
Functionally, MDM exhibited no adverse reactions after NMDTG treatment. Phagocytic
function of these cells remained unchanged after 8-hour incubation with 10 - 500 μM of
NDTG or NMDTG (Fig. 3.5b). Also, no deleterious reactive oxygen species were detected
after 2-hour exposure to parent drugs or their nanoformulations (Fig. 3.5d). Transmission
electron microscopy (TEM) was used to visualize particles within MDM (Fig. 3.4g-i).
NMDTG can be observed in intracellular compartments within the MDM (Fig. 3.4i). After
8-hours of NMDTG treatment, about 50% of the MDM cytoplasm was comprised of
vesicles containing nanoparticles. This was not seen with NDTG as only a few cells
showed any intracellular accumulation of nanoparticles (Fig. 3.4h).
3.3.4. Antiretroviral efficacy
To assess antiretroviral activity, HIV-1 RT activity and HIV-1p24 antigen
expression were evaluated in infected MDM. Cells were challenged with HIV-1ADA for up
to 30 days after a single 8-hour treatment with 100 µM drug. Native DTG and NDTG
efficacy was observed for up to 4 hours after drug treatment (Fig. 3.6a,b,d). Full inhibition
was only measured immediately after NDTG treatment (0 hours), with maximal inhibition
of only 65% following native DTG treatment. Native MDTG and NMDTG exhibited
improved antiretroviral efficacies compared to their parent drug counterparts. Significantly
lower RT activity was detected in media from NMDTG treated cells compared to NDTG
treatment beginning 12 hours (P = 0.0050), and up to 30 days (P < 0.0001), after drug
loading, with viral breakthrough beginning at day 30 (96% viral inhibition) (Fig. 3.6b,d).
Native MDTG mirrored these results, with viral breakthrough beginning at day 20 and
increasing to day 30 (83% inhibition at day 30) (Fig. 3.6a,d). HIV-1p24 antigen expression
(brown stain) verified all RT results (Fig. 3.6d).
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3.3.5. Effect of macrophage-released DTG on T cell infection
Prevention of spreading HIV-1 infection was assessed in PHA/IL-2 treated PBL
(lymphoblasts) after addition of conditioned media from drug-treated MDM. Conditioned
media, which contained drug released from MDM during a 24-hour period after drug
treatment, was used to treat lymphoblasts during spreading HIV-1MN infection. NMDTG
conditioned media significantly reduced HIV-1 RT activity in lymphoblasts compared to
NDTG conditioned media beginning at day 15 (P = 0.0018) (9 vs. 26% RT activity,
respectively), and maintained protection up to day 24 (P < 0.0001) (10 vs. 63% RT activity,
respectively) (Fig. 3.6c).

3.4.

Discussion
In the current study, a chemically modified DTG enabled the creation of poloxamer-

encased hydrophobic and lipophilic drug nanocrystals. Prodrugs can offer therapeutic
benefits over native compounds by providing reduced drug metabolism and toxicity. They
may also increase lipophilicity and thus improve cell membrane and tissue permeability of
drug [165]. Proof of concept for such advances are highlighted by antipsychotic drugs.
Indeed, these have become widely used as long-acting hydrophobic ester prodrugs [123].
Likewise, the creation of NMDTG improved drug to polymer interactions to form
stable nanocrystals and boosted delivery of the nanoformulated drug into MDM
autophagosomes [142]. The MDTG nanocrystals undergo slow intracellular dissociation
within endosomes and prodrug cleavage to protect the cell against viral challenge for up
to or beyond 25 days. Altogether, the creation of an ester prodrug of DTG using myristic
acid enabled intrinsic drug crystal formation and bioconversion. These reactions occurred
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in the presence of biological fluids containing esterases yielding pharmacologically active
medicines [160].
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3.5.

Figures

Figure 3. 1. Synthesis and characterization of MDTG.
(a) A fourteen-carbon fatty-acid modified DTG prodrug (MDTG) was synthesized creating
hydrophobic crystals at a final drug yield of 82.8%. (b) Absorption bands at 2915 cm-1 and
2850 cm-1 in the MDTG Fourier-transformation infrared spectrum (FTIR) illustrate the
methyl C-H asymmetric and symmetric stretching of the myristic acid alkyl group. Bands
at 1785 cm-1 in the myristoyl chloride and 1735 cm-1 in the MDTG FTIR spectrum
correspond to carbonyl C=O stretching of the myristic acid acyl halide that reacts as the
ester is formed in MDTG. (c) X-ray diffraction (XRD) analysis for DTG and MDTG
demonstrates the crystalline structures of both drugs. (d) Aqueous solubility of DTG and
MDTG demonstrates the decreased solubility of MDTG. **** P < 0.0001 DTG vs. MDTG.
(e) IC50 was determined in vitro in MDM by HIV-1 RT inhibition after DTG and MDTG
treatment over a range of concentrations (0.01 - 1,000 nM). Chemical modification of DTG
did not affect antiretroviral drug activity (56.7 and 62.5 nM for DTG and MDTG,
respectively; P = 0.8397). Results are shown as the mean + SEM of 3 replicates. Results
from d were analyzed by two-tailed Student’s t test (n = 10 DTG, 12 MDTG; t = 20.1,
degrees of freedom = 20). Results from e were analyzed by nonlinear regression least
squares fit.
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Figure 3. 2. Chemical characterization of MDTG.
Proton nuclear magnetic resonance (1H NMR) spectral analysis of DTG (a) shows the loss
of the peak corresponding to the 7-hydroxyl proton of DTG (a), while the spectrum of
MDTG (b) illustrates several unique peaks (b-e) that correspond to the protons present on
the covalently linked myristic acid moiety. (c) Carbon nuclear magnetic resonance (13C
NMR) spectral analysis of MDTG shows all 34 carbon atoms present on the modified drug.
(d) Positive electrospray ionization mass spectroscopy (ESI-MS) analysis shows the exact
mass of MDTG to be 629.33 (100%).
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Figure 3. 3. Nanoformulation stability and release kinetics.
Nanoformulations were synthesized by high-pressure homogenization using poloxamer
407 (P407) as the excipient for DTG and MDTG. (a-c) Formulation stability (up to 134
days) was measured by (a) particle hydrodynamic diameter (size), (b) polydispersity index
(PDI), and (c) zeta potential as determined by dynamic light scattering (DLS). NDTG and
NMDTG stability were tested at both 4 °C and 25 °C. (d-e) Nanoparticle release kinetics
were assessed by drug released from the nanoparticles during storage, in (d) freshly
manufactured (neat) formulation and (e) formulation diluted for in vivo administration. All
results are shown as the mean + SEM of at least 3 replicates.
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Figure 3. 4. Nanoparticle characterization.
(a-b) Particle morphology was assessed by scanning electron microscopy (SEM). (a) Note
that NDTG particles are of heterogeneous size and shape, and show both cuboidal and
rod-shaped morphologies. (b) NMDTG particles are more uniform, with dominant rodshaped morphologies (scale bars = 1 µm). (c) Drug uptake in MDM was measured over a
24-hour period with equal drug concentrations (100 µM). Uptake of NMDTG was at or
more than a half-log greater than its nonmodified control. **** P < 0.0001 NMDTG vs.
NDTG. #### P < 0.0001 MDTG vs. DTG. ^^ P = 0.0054, ^^^^ P < 0.0001 NMDTG vs.
MDTG. (d) Drug retention in MDM was measured over a 30-day observation period
demonstrating a log greater retention of the NMDTG compared to the nonmodified
control. ** P = 0.0048, **** P < 0.0001 NMDTG vs. NDTG. ### P = 0.0004 MDTG vs.
DTG. ^^^^ P < 0.0001 NMDTG vs. MDTG. (e) Drug release from MDM was measured
over a 14-day observation period demonstrating slowed and prolonged release from
NMDTG-treated cells through 10 days. * P = 0.0156, **** P < 0.0001 NMDTG vs. NDTG.
#### P < 0.0001 MDTG vs. DTG. ^^^^ P < 0.0001 NMDTG vs. MDTG. (f) Cell viability
was assessed in MDM by MTT assay 24 hours after NDTG or NMDTG treatment over a
range of concentrations (1-500 µM). Results were normalized to untreated control cells.
**** P < 0.0001 500 µM NDTG vs. control (untreated) cells. (g-i) Transmission electron
microscopy (TEM) of (g) control, (h) NDTG, and (i) NMDTG loaded MDM after 8-hour drug
treatment. Note the paucity of particles in the NDTG treated cells compared to the NMDTG
treated MDM (scale bars = 2 µm, upper panels; 500 nm, lower panels). Results are shown
as the mean + SEM of 3 biological replicates. Results from c,d,e,f were analyzed by twoway ANOVA with Bonferroni’s multiple comparison tests.
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Figure 3. 5. MDTG cleavage kinetics and MDM function after NDTG and NMDTG
treatments.
(a) Cell viability was assessed in MDMs by MTT assay 6 hours after NDTG or NMDTG
treatment over a range of concentrations (1 - 500 µM) for 8 hours. Results were
normalized to untreated control cells. (b) Phagocytic activity was assessed in MDMs by
VybrantTM phagocytosis assay after NDTG or NMDTG treatment over a range of
concentrations (10 - 500 µM) for 8 hours. Results were normalized to untreated control
cells. (c) Cytotoxicity was assessed in MDMs by LDH assay 24 hours after 100 and 400
µM NDTG or NMDTG treatment for 8 hours. Results were normalized to cell lysate control.
(d) Reactive oxygen species generation was assessed in MDMs by DCFDA assay after
100 and 400 µM NDTG or NMDTG treatment for 2 hours. Results were normalized to
DCFDA-treated positive control cells. (e) Cleavage of MDTG was assessed ex vivo in
whole mouse blood. Known concentrations of MDTG were spiked into blood, blood diluted
10X in PBS, blood that was immediately added to acetonitrile (ACN), or blood spiked with
an esterase inhibitor cocktail. At various time points samples were collected and analyzed
for MDTG levels by UPLC-MS/MS. All results are shown as the mean + SEM of at least 3
biological replicates.
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Figure 3. 6. Antiretroviral efficacy.
(a-b) HIV-1 RT activity of (a) DTG and MDTG, and (b) NDTG and NMDTG treated MDM.
** P = 0.0039, *** P = 0.0007, **** P < 0.0001 MDTG vs. DTG and NMDTG vs. NDTG. (c)
Prevention of spreading viral infection was assessed in human peripheral blood
lymphocytes (PBLs) following addition of media conditioned from drug-treated MDM.
NMDTG conditioned media significantly reduced HIV-1 RT activity in PBLs compared to
NDTG conditioned media beginning at day 15 and maintained protection up to day 24. **
P = 0.0018, **** P < 0.0001 NMDTG vs. NDTG. (d) Representative HIV-1p24 staining
(brown) of virus-infected MDM treated with native or nanoformulated drugs are shown.
For all, uninfected cells without treatment served as negative controls. HIV-1-infected cells
without treatment served as positive controls. Results were normalized to positive control
cells. All results are shown as the mean + SEM of 3 biological replicates. Results from
a,b,c were analyzed by two-way ANOVA with Bonferroni’s multiple comparison tests.
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CHAPTER 4 – SMALL ANIMAL TESTING OF NMDTG**

4.1.

Introduction
Animal models have long been used for scientific purposes in the research setting

to attempt to bridge the translational gap to the clinic, however, no animal model can
completely recapitulate human disease. Even still, animal models provide key insights into
disease pathogenesis, drug safety, and drug efficacy. They can be used in screening
efforts for development of therapies for eventual human use. In the current report NMDTG
was tested to determine the sustained plasma drug levels and consequential superior in
vivo therapeutic efficacy. Pharmacokinetic (PK) studies were performed in male Balb/cJ
mice to compare blood and plasma concentrations, as well as tissue distribution, of NDTG
and NMDTG formulations. PK evaluation determined proper timing for subsequent
pharmacodynamic (PD) studies. Finally, two humanized murine models of HIV-1 infection,
the human peripheral blood lymphocyte-reconstituted and the human CD34+
hematopoietic stem cell-reconstituted models, were used to determine the therapeutic
efficacy of NMDTG. PK and PD profiles in mice were significantly improved over a native
drug formulation, exhibiting 5.3-fold extension in drug apparent half-life, broad tissue
distribution, and increased antiretroviral efficacy. Our data provide evidence that DTG
conversion into a long-acting, slow release formulation is readily achievable with
reductions in dose and dosing intervals that could extend to one month or longer.

**

Adapted from Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, Su
H, Kanmogne GD, Poluektova LY, Gorantla S, McMillan J et al: Creation of a long-acting
nanoformulated dolutegravir. Nat Commun (2018) 9(1):443. To view a copy of the
Creative
Commons
Attribution
4.0
International
License,
visit
http://creativecommons.org/licenses/by/4.0/.
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4.2.

Methods

4.2.1. Reagents
DTG was a generous gift from ViiV Healthcare (Research Triangle Park, NC).
Poloxamer 407 (P407) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture grade water
(endotoxin-free), acetonitrile (ACN), methanol, LC-MS-grade water, and TRIzol reagent
were purchased from Fisher Scientific (Hampton, NH). FITC mouse anti-human CD45,
Alexa Fluor 700 mouse anti-human CD3, APC mouse anti-human CD4, BV421 mouse
anti-human CD8, PE mouse anti-human CD14, and PE-Cy5 mouse anti-human CD19
were purchased from BD Biosciences (San Jose, CA). Monoclonal mouse anti-human
HIV-1p24 (clone Kal-1), monoclonal mouse anti-human leukocyte antigen (HLADP/DQ/DR; clone CR3/43), and the polymer-based HRP-conjugated anti-mouse
EnVision+ secondary were purchased from Dako (Carpinteria, CA).
4.2.2. Pharmacokinetics in mice
Male Balb/cJ mice (6-8 weeks of age; Jackson Labs, Bar Harbor, ME) were
injected with NDTG or NMDTG (45 mg/kg DTG-eq.) intramuscularly (IM; caudal thigh
muscle) in a volume of 40 µL/25 g mouse. For injections, NDTG and NMDTG were diluted
to 28.1 mg DTG/mL in endotoxin-free water and 42.3 mg MDTG/mL in HEPES buffer,
respectively. Twenty-five µL of whole blood was collected by cheek puncture into 1 mL
ACN at 1, 3, 7, 14, 21, 28, 35, 42, 49, and 56 days after drug administration. Animals were
humanely euthanized using isoflurane followed by cervical dislocation at 28 and 56 days,
and tissues (spleen, liver, lymph nodes, lungs, kidneys, gut-associated lymphoid tissue
(GALT), and brain) were collected for drug quantitation. Drug concentration in whole blood
and tissues was determined by UPLC-MS/MS using a Waters Acquity UPLC- Xevo TQ-S
micro mass spectrometry system (Milford, MA). For blood analysis, 10 µL of internal
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standard (IS) solution was added to each sample. DTG-d3 and myristoylated cabotegravir
(MCAB) were used as IS for DTG and MDTG analysis, respectively. The final IS
concentration was 50 ng/mL after reconstitution. Samples were then vortexed and
centrifuged at 17,000 x g for 10 min at 4 °C. Supernatants were dried using speed vacuum,
reconstituted in 100 µL 50% (v/v) ACN in LC-MS-grade water, and 10 µL subsequently
injected for DTG and MDTG UPLC-MS/MS analysis. Standard curves were prepared in
blank mouse blood in the range of 0.2 – 2,000 ng/mL of the corresponding drug. For tissue
analysis, 50 - 200 mg of each sample was homogenized in four volumes of 90% (v/v) ACN
in LC-MS-grade water using a Qiagen TissueLyzer II (Valencia, CA). Subsequently, 80 µL
of ACN, 10 µL of 50% ACN (v/v) in LC-MS-grade water, and 10 µL IS was added to 100
µL of tissue homogenate. Standard curve samples were prepared the same way as the
study samples, except for using 10 µL of 10X analyte spiking solution that results in a final
concentration range of 0.5 - 2,000 ng/mL. Chromatographic separation of 10 µL sample
injections was achieved with an ACQUITY UPLC-BEH Shield RP18 column (1.7 µm, 2.1
mm x 100 mm) using a 10-min gradient of mobile phase A (7.5 mM ammonium formate in
Optima-grade water adjusted to pH 3 using formic acid) and mobile phase B (100%
Optima-grade ACN) at a flow rate of 0.25 mL/min. The initial mobile phase composition
was 40% B for the first 3 min at which time it was increased to 86% B over 30 seconds
and held constant for 5 min. Mobile phase B was then reset to 40% over 15 seconds and
held for 1.25 min for equilibration. MDTG was quantified using a 7-min gradient of the
same mobile phases at a flow rate of 0.35 mL/min. The initial mobile phase composition
was 80% B for the first 4.5 min at which time it was increased to 95% B over 15 seconds
and held constant for 1 min. Mobile phase B was then reset to 80% over 15 seconds and
held for 1 min. DTG and MDTG were detected at cone voltages of 10 and 16 volts and
collision energies of 25 and 44 volts, respectively. Multiple reaction monitoring (MRM)
transitions used for DTG, MDTG, DTG-d3, and MCAB were 420.075 > 277.124, 630.2 >
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420.067, 422.841 > 129.999, and 616.277 > 406.094 m/z, respectively. Spectra were
analyzed and quantified by MassLynx software version 4.1. Quantitations are based upon
drug peak area to internal standard peak area ratios.
4.2.3. In vivo measures of HIV-1 restriction and protection

NOD/scid-IL-2Rγcnull (NSG) mice (6-7 weeks of age; Jackson Labs, Bar
Harbor, ME) were administered a single IM injection in a volume of 40 µL/25 g
mouse of NDTG or NMDTG at a concentration of 45 mg/kg DTG-eq. on day 0 for
measures of relative viral restriction. Mice were then reconstituted with 25 x 106
human peripheral blood lymphocytes (hu-PBL) per mouse 4- or 19-days post drug
treatment by IP injection. Next, mice were challenged 10 days post hu-PBL
reconstitution with HIV-1ADA at 14- or 29-days post drug treatment by IP injection
at a TCID50 of 2 x 104 per mouse. Blood samples were collected one day before
HIV-1 infection for determination of T cell populations by flow cytometry, including:
CD45+, CD3+, CD4+, CD8+, and CD4:CD8+ ratios, and regularly after treatment for
determination of drug levels by UPLC-MS/MS. Animals were humanely euthanized
10 days post HIV-1 challenge and blood, plasma, and tissues were collected.
Plasma was saved for viral load (HIV-1 RNA) quantitation using the Roche
Amplicor and TaqMan-48 system [HIV-1 kit V2.0 according to the manufacturer’s
instructions (Indianapolis, IN)]. Blood and tissue drug concentrations were
determined by UPLC-MS/MS as described above. Tissue immunohistochemistry
was performed for HIV-1p24 antigen and HLA-DP/DQ/DR [166,167]. Briefly,
tissues were fixed in 4% PFA overnight and embedded in paraffin. Five-micron
thick tissue sections were cut and mounted on glass slides, which were stained for
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HIV-1p24 or HLA-DP/DQ/DR and developed with DAB. The nuclei were
counterstained with Mayer’s hematoxylin and visualized with a 20x objective on a
Nikon Eclipse E800 microscope (Melville, NY) with Nuance EX multispectral
imaging system (PerkinElmer, Hopkinton, MA). The number of HIV-1p24+ and
HLA-DP/DQ/DR+ cells per section were counted and expressed as percentage of
HIV-1p24+ cells/HLA-DP/DQ/DR+ cells per section. For viral protection tests, NSG
mice were reconstituted at birth with CD34+ HSC isolated from umbilical cord blood
[168]. Reconstituted mice were administered a single IM dose of NMDTG at a
concentration of 45 mg/kg DTG-eq. at 22 weeks of age. Mice were challenged two
weeks post drug treatment with 2 x 104 TCID50 of HIV-1ADA by IP injection. Blood
was collected by cheek puncture into EDTA-blood collection tubes three weeks
post HIV-1 challenge; and blood and plasma were collected to determine drug
levels and viral load, respectively. Plasma was used for quantitative viral load
(measurements of HIV-1 RNA) using the Roche Amplicor and TaqMan-48 system.
Blood and tissue drug concentrations were determined by UPLC-MS/MS as
described above. For the detection of viral RNA copies, RNAscope was performed
(Advanced Cell Diagnostics, Hayward, CA). A channel 1 anti-sense HIV-1 Clade
B target probe, which contains 78 probe pairs targeting base pairs 854-8291 of
HIV-1, was used in the single-plex chromogenic assay. Briefly, 5 µm thick deparaffinized and dehydrated formalin-fixed paraffin-embedded (FFPE) spleen and
lymph node sections were pretreated with hydrogen peroxide at room temperature
for 10 min, boiling citrate buffer for 8 min then protease IV at 40 °C for 15 min in a
HybEZ hybridization oven. Hybridization with target probe, pre-amplification,
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amplification and chromogenic detection using DAB was carried out as per
manufacturer’s instructions in HybEZ oven at 40 °C. Positive expression was
indicated by the presence of brown dots in the infected cells and scored using the
criteria: 0 = no staining or < 1 dot/10 cells, 1 = 1-3 dots/cell, 2 = 4-9 dots/cell with
no, or very few, dot clusters, 3 = 10-15 dots/cell and < 10% dots are in clusters, 4
= > 15 dots/cell and > 10% dots are in clusters. Scoring was performed at 20x
magnification. For tissue DNA and RNA isolation, each sample was homogenized
using a Qiagen TissueLyzer II (Valencia, CA) and Qiagen AllPrep DNA/RNA Mini
Kit (Hilden, Germany) utlilized as per manufacturer’s instructions. cDNA was
produced from RNA using ThermoScientific Verso cDNA Synthesis Kit (Vilnius,
Lithuania) as per manufacturer’s instructions. Cell-associated HIV-1 RNA and
DNA were quantified by semi-nested real-time PCR and confirmed by droplet
digital PCR [169,170].
4.2.4. Statistics
For all studies, data were analyzed using GraphPad Prism 7.0 software (La Jolla,
CA) and presented as the mean ± the standard error of the mean (SEM). Sample sizes
were not based on power analyses. For comparisons of two groups, Student’s t test (twotailed) was used. Tissue drug levels, T cell populations, viral RNA and DNA, and viral load
were analyzed by one-way ANOVA with Bonferroni correction for multiple-comparisons.
For studies with multiple time points, two-way factorial ANOVA and Bonferroni’s post-hoc
tests for multiple comparisons were performed. Animal studies included a minimum of six
animals per group unless otherwise noted. Extreme outliers beyond the 99% confidence
interval of the mean and 3-fold greater than the SEM were excluded. Significant
differences were determined at P < 0.05.
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4.2.5. Study Approval
All experimental protocols involving the use of laboratory animals were approved
by the UNMC Institutional Animal Care and Use Committee (IACUC) ensuring the ethical
care and use of laboratory animals in experimental research. All animal studies were
performed in compliance with UNMC institutional policies and NIH guidelines for
laboratory animal housing and care. Human blood cells were isolated by leukapheresis
from HIV-1/2 and hepatitis seronegative donors and were deemed exempt from approval
by the Institutional Review Board (IRB) of UNMC. Human CD34+ hematopoietic stem cells
were isolated from umbilical cord blood and are exempt from UNMC IRB approval.

4.3.

Results

4.3.1. Pharmacokinetics in mice
Male Balb/cJ mice were administered a single 45 mg/kg DTG-equivalent
(equimolar DTG) dose of NDTG or NMDTG intramuscularly (IM) into the caudal thigh
muscle to determine pharmacokinetics (PK) over 8 weeks. Whole blood and tissue
samples were analyzed by ultra-performance liquid chromatography-tandem mass
spectroscopy (UPLC-MS/MS) to determine parent and prodrug levels. Neither NDTG nor
NMDTG treatments had any adverse effect on animal weight (Fig. 4.1a). NMDTG
displayed a greatly reduced DTG decay curve compared to NDTG, with higher blood drug
levels beginning at day 14 (689.8 ng/mL) and extending to day 56 (88.8 ng/mL) (Fig. 4.1b).
At day 28, the blood drug levels were 272.6 ng/mL for NMDTG while NDTG was at or
below the limit of quantitation (< 4 ng/mL). DTG apparent half-life was increased from 61.9
hours for NDTG to 330.4 hours for NMDTG (Table 4.1). Similarly, DTG mean residence
time (MRT) was more than 3-fold longer with NMDTG than NDTG (104.2 versus 348.8 hr,
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respectively). The longer apparent half-life for NMDTG was the result of an approximately
5-fold increase in volume of distribution (V( /F) (NDTG - 4.55, NMDTG - 22.10 L/kg);
whereas, clearance (CL/F) was essentially the same compared to NDTG (NDTG - 0.051,
NMDTG - 0.046 L/hr/kg). Average blood DTG levels for NMDTG remained above the PAIC90 (64 ng/mL) for the entire 8-week test period, and above four times the PA-IC90 for 28
days. DTG concentrations for NDTG treated mice were above the PA-IC90 and four times
the PA-IC90 for 14 days (328.3 ng/mL). The prodrug was detectable in blood over the first
3 days. At day 28, NMDTG-treated mice had significantly higher DTG levels than NDTGtreated mice in spleen, lymph node, gut-associated lymphoid tissue (GALT), liver, lung,
and kidney tissues (P < 0.0001). Drug levels in tissues were between 25- and 123-fold
higher with NMDTG treatment than NDTG at day 28 (GALT and liver, respectively).
NMDTG-treated animals maintained detectable drug levels at day 56 (8.0, 31.2, 21.5,
17.6, 45.8, and 34.7 ng/g for spleen, lymph node, GALT, liver, lung and kidney,
respectively), while no drug was detected in tissues from NDTG-treated animals (Fig. 4.1ch).
4.3.2. In vivo measures of HIV-1 restriction and protection
For initial screening of viral restriction by NDTG and NMDTG, NOD/scid-IL-2Rγcnull
(NSG) mice were reconstituted by intraperitoneal (IP) injection of human peripheral blood
lymphocytes (hu-PBLs) 4- or 19-days post drug treatment generating hu-PBL-NSG, mice.
Mice were administered a single IM dose of NDTG or NMDTG at a concentration of 45
mg/kg DTG-eq. on day 0 (Fig. 4.2a) then challenged 10 days post hu-PBL reconstitution
with 2 x 104 TCID50 of HIV-1ADA administered by IP injection. Animals were euthanized 10
days post HIV-1 challenge, and blood, plasma, and tissues were collected for drug levels,
human T cell counts, viral load and HIV-1p24 expression. Neither NDTG nor NMDTG
treatment adversely affected animal weights (Fig. 4.3a,e). Enhanced levels of viral

74
restriction were observed by NMDTG over NDTG treatments when mice were challenged
two or four weeks after a single IM drug dose. Levels of viral reductions were 3.0- and 1.2log10 in plasma viral load compared to HIV-1 infected controls and 1.8- and 1.1-log10
decreases in plasma viral load for NMDTG- compared to NDTG-treated mice, when
challenged two weeks or four weeks post-treatment, respectively (Fig. 4.2b,d). HIV-1p24
expression was also determined in paraffin-embedded spleen sections. When challenged
two weeks post-treatment, NMDTG provided restriction of viral infection in spleen (Fig.
4.2c,f). NMDTG treatment also reduced viral p24 expression in spleen when challenged
four weeks post-treatment (4.4% of HLA-DP/DQ/DR+ cells compared to 15.6 and 14.6%
for HIV-1 infected controls (P = 0.0006) and to NDTG (P < 0.0025; Fig. 4.2e,g). With
NMDTG treatment, average blood DTG levels in the hu-PBL-NSG mice remained above
the PA-IC90 (64 ng/mL) for the entire 52-day test period (125.5 ng/mL) and above four
times the PA-IC90 for 28 days (275.3 ng/mL; Fig. 4.2h). NDTG treatment remained above
the PA-IC90 for 28 days (78.3 ng/mL) and above the four times the PA-IC90 for up to 21
days (220.4 ng/mL). Tissue DTG concentrations in spleen, GALT, liver, lung, and kidney
are shown at days 24, 39, and 52 (Fig. 4.2i-m). Drug levels in tissues were on average
2.1-fold higher after NMDTG treatment than NDTG on day 24. Little to no drug was
detected in tissues from DTG-treated animals beginning at day 39, with only kidney having
measurable drug levels (4.1 ng/g). NMDTG-treated animals maintained detectable drug
levels through day 52.
As graft-versus-host disease induces CD4+ T cell activation in hu-PBL mice, a
second murine model was employed to assess in vivo efficacy of NMDTG against viral
challenge. This was used to both extend and validate the initial screening tests. Here, the
ability of NMDTG to protect against a significant viral challenge of 2 x 104 TCID50 HIV-1ADA
was determined in NSG mice reconstituted at birth with CD34+ human hematopoietic stem
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cells (HSC) obtained from human cord blood. Importantly, these reconstituted mice show
quiescent lymphocyte profiles and as such reflect what would occur in a HIV-1 challenged
human host. Thus, these mouse validation tests would more closely mimic what would
occur during pre-exposure prophylaxis (PrEP). NMDTG was the sole tested formulation
for the longer-term protection studies since PK tests for NDTG showed drug levels below
the PA-IC90 by 21 days and no detectable drug by day 28 (Fig. 4.1b-h). NDTG treatment
also recorded limited long-term viral restriction (Fig. 4.2). Thus, for these mice, a single
IM dose of NMDTG was administered at a concentration of 45 mg/kg DTG-eq. at 22 weeks
of age (Fig. 4.4a). Mice were challenged two weeks following drug treatment with 2 x 104
TCID50 of HIV-1ADA by IP injection. Mice were bled three weeks post HIV-1 challenge; and
blood and plasma collected to assess drug levels and viral loads. Neither NMDTG
treatment nor viral challenge had an adverse effect on animal weight throughout the
experimental period (data not shown). Average blood DTG levels remained above four
times the PA-IC90 (279.1 ng/mL; 4.4 times the PA-IC90 at day 35) for the entire length of
the study (Fig. 4.4b). Tissue drug levels in spleen, GALT, lung, and liver were concordant
with previous experiments at day 35 (Fig. 4.4c). NMDTG treated mice showed protection
when challenged with virus two weeks after a single IM dose; with detectable plasma viral
load in a single NMDTG-treated animal and one at the limit of detection (Fig. 4.4d). Seminested real-time PCR confirmed protection against viral challenge with cell-associated
HIV-1gag DNA and RNA in NMDTG-treated spleen, GALT, lung, bone marrow, and liver
below the limit of detection (Fig. 4.4e,f). HIV-1 RNAscope was performed on spleen and
lymph node sections, and HIV-1 RNA staining was scored according to the manufacturer’s
pre-determined criteria in a blinded manner (Fig. 4.4g,h). Due to high technique sensitivity
(detection limit of 1 viral RNA copy/cell using 78 probes spanning 7,437 base pairs) a
score of < 1 was considered background. HIV-1 RNA staining score for both HIV-1infected and NMDTG-treated spleen (2.2 versus 0.86, respectively; P = 0.0418) and lymph
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node tissue sections (3.4 vs. 1.4, respectively; P = 0.0027) demonstrated NMDTG
protection.

4.4.

Discussion
PK and PD profiles of NMDTG in mice were significantly improved over a native

drug formulation, exhibiting 5.3-fold extension in drug apparent half-life, broad tissue
distribution, and increased antiretroviral efficacy. No mouse model exactly reflects PrEP,
thus murine models of both viral restriction and protection were implored in this study. It
is noteworthy that the evaluation of viral restriction as performed in hu-PBL mice failed to
provide protection against viral challenge by less than one month, as shown by detectable
plasma viral load. This likely reflects enhancement in viral susceptibility in the animals
based on the large numbers/percentages of activated lymphocytes due to xenoreactivity
leading to graft-versus-host disease, timing of human cell reconstitution, larger viral
challenge, route of viral challenge, and monotherapy approach [171-175].
CD34+ HSC reconstituted NSG mice better reflect human biology as there is no
graft-versus-host disease and the reconstitution contains monocyte-macrophages as well
as CD4+ and CD8+ T lymphocytes [176]. To these ends, this model was used for
confirmatory studies. Indeed, cells were quiescent prior to viral challenge. Most
importantly, NMDTG treated HSC-NSG mice demonstrated plasma viral load, as well as
tissue viral RNA/DNA copies, below the limit of detection in five of seven animals for two
weeks against HIV-1 challenge following a single nanoparticle injection. Due to biological
limitations in the animal models used, protection in all animals was not achieved. These
results reflect what was observed in humans who are at risk of viral infection despite
optimal PrEP treatment [177]. Due to experimental limitations, the possibility cannot be
excluded that the high concentrations of drug present during analysis could suppress
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potential breakthrough of HIV-1 infection. Based on the intrinsic properties of drug stability
and with retention in MDMs in tissues, such chemical prodrug modifications led to the
formation of a second drug reservoir beyond the injection site. Such improvements in
antiretroviral drug structure and packaging can not only improve drug compliance, but also
could reduce systemic toxicities.
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4.5.

Figures

Figure 4. 1. Pharmacokinetics in mice.
Balb/cJ mice were administered a single IM dose of NDTG or NMDTG (45 mg/kg DTGeq.) to determine pharmacokinetic (PK) profiles. (a) Animal weights were monitored for
the length of the study to assess animal health. (b) Blood DTG and MDTG concentrations
were analyzed by UPLC-MS/MS. Solid lines indicate [DTG], while the dashed line
indicates [MDTG] from NMDTG treatment. Dotted lines indicate the PA-IC90 (64 ng/mL)
and four-times the PA-IC90 (256 ng/mL). (c-h) Tissue DTG concentrations were analyzed
by UPLC-MS/MS. (c) Spleen, (d) lymph node, (e) GALT, (f) liver, (g) lung, and (h) kidney
DTG levels are shown at days 28 and 56. **** P < 0.0001. Results are shown as the mean
+ SEM of at least 6 biological replicates. Results from c-h were analyzed by two-tailed
Student’s t test (for all, n = 6 NDTG, 6 NMDTG, degrees of freedom = 10; c - t = 14.4; d t = 16.4; e - t = 9.3; f - t = 17.3; g - t = 30.1; h - t = 22.7).
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Figure 4. 2. Viral restriction in PBL reconstituted mice.
NSG mice were treated according to the scheme illustrated in (a). Uninfected mice without
treatment served as negative controls. HIV-1-infected mice without treatment served as
positive controls. Plasma viral load was measured at terminal euthanasia after HIV-1
challenge (b) two-weeks and (d) four-weeks post drug treatment. ** P < 0.01, *** P <
0.001. Spleen sections were stained for HIV-1p24 and HLA-DP/DQ/DR, and HIV-1p24+
and HLA-DP/DQ/DR+ cells were quantified. Results are represented as percent HIV1p24/HLA-DP/DQ/DR+ cells after HIV-1 challenge (c) two-weeks and (e) four-weeks post
drug treatment. ** P < 0.001, *** P < 0.001, **** P < 0.0001. Representative HLADP/DQ/DR (top) and HIV-1p24 (bottom) staining (brown) of spleen sections quantified
after HIV-1 challenge (f) two-weeks and (g) four-weeks post drug treatment. (h) Blood
DTG concentrations were analyzed by UPLC-MS/MS. Dotted lines indicate the PA-IC90
(64 ng/mL) and four-times the PA-IC90 (256 ng/mL). (i-m) DTG concentrations were
analyzed by UPLC-MS/MS in spleen (i), GALT (j), liver (k), lung (l), and kidney (m). Drug
levels were tested at days 24, 39, and 52. * P = 0.0280, ** P < 0. 01, *** P < 0. 001, **** P
< 0.0001. Results are shown as the mean + SEM of 5-6 biological replicates (Uninfected
group – n = 3). Findings obtained from b-e were analyzed by one-way ANOVA with
Bonferroni’s multiple comparison tests. Results from i-m were analyzed by two-tailed
ANOVA with Bonferroni’s multiple comparison tests.
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Figure 4. 3. Animal weights and flow cytometry tests of PBL reconstituted mice.
(a,e) Animal weights were monitored throughout the length of the study to assess animal
health. Cell phenotyping analysis of human CD4+ (b,f) and CD8+ (c,g) T cell populations
determined from CD3+ lymphocytes in the total CD45+ cell population by flow cytometry.
(d,h) CD4:CD8+ cell ratios were calculated. All groups were analyzed before infection and
at the time of terminal euthanasia. Results are shown for the two-week (a-d) and fourweek (e-h) viral challenges. Uninfected mice without treatment served as negative
controls. HIV-1-infected mice without treatment served as positive controls. Results are
shown as the mean + SEM of 5-6 biological replicates (Uninfected group – n = 3).
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Figure 4. 4. Protection against HIV-1 challenge in CD34+ humanized mice.
CD34+ hematopoietic stem cell (HSC)- reconstituted NSG mice were treated with NMDTG
according to the scheme illustrated in (a). HIV-1-infected mice without treatment served
as positive controls. (b) Blood DTG concentrations were analyzed by UPLC-MS/MS.
Dotted lines indicate the PA-IC90 (64 ng/mL) and four-times the PA-IC90 (256 ng/mL). (c)
DTG concentrations were also analyzed in spleen, GALT, lung, and liver samples. (d)
Plasma viral load was measured three-weeks after HIV-1 challenge. (e) DNA and (f) RNA
semi-nested real-time PCR was performed on spleen, GALT, lung, bone marrow, and
liver. (g) HIV-1 RNAscope was performed on spleen and lymph node sections and scored
according to amount of positive staining [0 = no staining or < 1 dot/10 cells, 1 = 1-3
dots/cell, 2 = 4-9 dots/cell with no, or very few, dot clusters, 3 = 10-15 dots/cell and < 10%
dots are in clusters, 4 = > 15 dots/cell and > 10% dots are in clusters]. Anything scoring
less than or equal to 1 was considered as background. (h) Representative HIV-1
RNAscope staining (brown) of spleen (top) and lymph node (bottom) sections are shown.
* P < 0.05, ** P < 0. 01. Results are shown as the mean + SEM of 5 positive control (5
female) and 7 NMDTG treated (5 female, 2 male) animals. Results were analyzed by twotailed Student’s t test (n = 5 HIV-1 control, 7 MDTG; degrees of freedom = 10).
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Tables

Table 4. 1. Pharmacokinetic parameters in mice.
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CHAPTER 5 – NON-HUMAN PRIMATE TESTING OF NMDTG††

5.1.

Introduction
Antiretroviral

drug

(ARV)

therapy

allows

those

infected

with

human

immunodeficiency virus (HIV) to live normal productive lives [3,178]. Nonetheless,
adherence to lifelong daily multidrug regimens and viral resistance continue [71,179-183].
End organ disease, drug-drug interactions, cost, short pharmacologic duration and access
are further limitations. It is posited that long-acting ARVs can overcome these restrictions
[71-73,184,185]. In a step to transform existing ARVs into long-acting medicines, the
hydrophobicity and lipophilicity of ARVs can be increased through carboxy-ester
myristoylation, affecting tissue and cell penetrance [81,112]. In the current report, this
approach was developed for dolutegravir (DTG), a second-generation integrase strand
transfer inhibitor with high viral resistance barriers [84,186]. Native orally administered
DTG demonstrates a plasma half-life of 13-14 h [187-189] with > 99% plasma albumin
and alpha 1-acid glycoprotein binding. A daily or twice-daily dosing is required to maintain
therapeutic plasma concentrations above a protein-adjusted 90% inhibitory concentration
(PA-IC90) of 64 ng/mL [84,187-189]. To extend the pharmacokinetic properties of DTG a
nanoformulated prodrug derivative (coined NMDTG) was made. Forty-five mg/kg
intramuscular injections led to drug levels in mice above the PA-IC90 for 56 days [190] and
was then affirmed in non-human primates.

††

Adapted from McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B,
Callen S, Gautam N, Alnouti Y, Edagwa B, Gendelman HE et al: Pharmacokinetics of a
long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob
Agents Chemother (2018) 62(1). To view a copy of the Creative Commons Attribution 4.0
International License, visit http://creativecommons.org/licenses/by/4.0/.
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5.2.

Methods

5.2.1. NMDTG preparation and characterization
Myristoylated DTG (MDTG) was prepared by a one-step synthesis then encased
into a nanoformulation [190]. Synthesis and quality control measures were maintained
through the Nebraska Nanomedicine Production Plant using Good Laboratory Practice
(GLP) protocols following USA Food and Drug Administration (FDA) guidelines [191]. The
prepared suspensions were homogenized at 20,000 psi using an Avestin EmulsiFlex-C3
high-pressure homogenizer (Avestin, Inc., Ottawa, ON). Particle sizes, polydispersity
indices and zeta potentials were determined by dynamic light scattering (Malvern
Zetasizer Nano ZSP, Malvern Instruments, Westborough, MA). MDTG concentrations in
the nanosuspensions were determined by ultra-performance liquid chromatography
tandem mass spectrometry (UPLC-MS/MS; Waters Acquity XevoTQ-S micro system;
Waters Corp, Milford, MA). Endotoxin was determined by Lonza Limulus Amebocyte
Lysate PYROGENT-500 tests (Lonza, Walkersville, MD). Animal studies were conducted
in accordance with the University of Nebraska Medical Center Institutional Animal Care
and Use Committee following federal guidelines. Three male rhesus macaques (9-10 kg;
purchased from PrimeGen) were anesthetized with 10 mg/kg ketamine and injected
intramuscularly (IM) with undiluted NMDTG suspension (38.5 mg/kg in 2.67-3.50 mL).
Blood was collected into potassium EDTA tubes before NMDTG administration, days 1, 4
and 7 after administration, and weekly thereafter to day 91. Plasma and peripheral blood
mononuclear cells (PBMCs) were obtained for complete blood counts, metabolic panels
and DTG and MDTG drug quantitation. These were performed by the Nebraska Medical
Center Pathology and Microbiology laboratory and by the Nebraska Nanomedicine
Production Plant GLP laboratory using UPLC-MS/MS, respectively. Animal health and
injection site reactions were monitored daily.
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5.2.2. UPLC-MS/MS quantitation of MDTG and DTG in monkey plasma and
PBMCs
DTG and MDTG concentrations in monkey plasma and PBMCs were determined
by UPLC-MS/MS using a Waters ACQUITY H-class UPLC/Xevo TQ-S micro system
(Waters, Milford, MA). For plasma analysis, 50 μL of plasma was added to 1 mL of icecold LC/MS-grade acetonitrile and 10 μL of internal standard (IS) solution (500 ng/mL
each DTG-d3 and myristoylated cabotegravir (MCAB)). For PBMC analysis, 1 mL ice-cold
LC/MS-grade acetonitrile was added to pelleted cells (~1 x 108 cells) and 10 μL IS solution
was added. Plasma and PBMC samples were then vortexed for 3 min and centrifuged at
17,000 x g for 10 min at 4 °C. Supernatants were dried using a speed vacuum and
reconstituted in 100 μL 50% (v/v) LC/MS-grade acetonitrile in water. Standard curves (0.2
-2000 ng/mL) of DTG and MDTG were prepared in blank monkey plasma and PBMCs.
Chromatographic separation of 10 μL sample was achieved using an ACQUITY UPLCBEH Shield RP18 column (1.7 μm, 2.1 mm x 100 mm) with a 10-min gradient of mobile
phase A (7.5 mM ammonium formate in LC/MS-grade water adjusted to pH 3 with formic
acid) and mobile phase B (100% LC/MS-grade acetonitrile) at a flow rate of 0.25 mL/min.
The initial mobile phase composition was 40% B for the first 3 min and was increased to
86% B in 0.5 min and held constant for 5 min. Mobile phase B was then reset to 40% in
0.25 min and the column was equilibrated for 1.25 min before the next injection. DTG and
MDTG were detected at cone voltages of 10 and 16 volts and collision energies of 25 and
44 volts, respectively. Multiple reaction monitoring (MRM) transitions used for DTG,
MDTG, DTG-d3, and MCAB were 420.075 > 277.124, 630.2 > 420.067, 422.841 >
129.999, and 616.277 > 406.094 m/z respectively. Spectra were analyzed and quantified
by MassLynx software version 4.1. All calculations were made using analyte peak area to
IS peak area ratios.
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5.2.3. Nanomedicine Production Plant Good Laboratory Practice (GLP) Facility
Production of NMDTG
The Operational Unit and Quality Assurance Unit work together, but independently
of each other, to put into place the protocols and guidelines, which were followed during
the manufacturing of NMDTG in the Good Laboratory Practice (GLP) Facility.
The Operational Unit was responsible for following approved protocols and
standard operating procedures (SOPs). All of the equipment followed strict protocols for
calibration and cleaning before and after use. A witness verified all procedures performed
in the GLP facility and every step was initialed and dated by the operator and verifier. The
operator and verifier followed specific protocols for Personal Protective Equipment (PPE)
and behavior once in the GLP facility. This is a highly-restricted access facility. Due to the
importance and quality of work being done only Nebraska Nanomedicine Production Plant
employees are granted access. All steps of the approved protocol were documented
during manufacturing.
The Quality Assurance Unit was responsible for monitoring this study to assure
that the facilities, equipment, personnel, methods, practices, records, and controls were
in conformance with the regulations. The Quality Assurance Unit is entirely separate from
and independent of the personnel engaged in the direction and conduct of the study. They
also maintained a copy of the master schedule sheet, copies of all protocols and
determined that no deviations from approved protocols or standard operating procedures
were made without proper authorization and documentation.
The balances used two weight standards (10 and 200 g) for calibration checks.
The pH probe is standardized using three pH standard buffers (pH 4.0, 7.0 and 10.0) to
give a standardized pH slope. All pipets had been calibrated. The Malvern Zetasizer Nano
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ZSP, which is used for size, polydispersity index and zeta potential measurements, used
a 60 nm standard to check calibration. These steps were done before each use.
Equipment such as the Avestin Emulsiflex C3 High Pressure Homogenizer have
cleaning protocols which were implemented before and after use. The homogenizer had
at least 500 mL of methanol, then sodium hydroxide (NaOH) and lastly 1500 mL of Water
For Injection (WFI) circulated through it before and after each manufacturing run. The
homogenizer also contains some removable parts which were placed in the oven to bake
at 200 ˚C for at least 60 min. All of the glassware that is used in the GLP facility is also
baked at 200 ˚C for 60 min to remove pyrogens.
Equipment with parts that cannot be removed to be cleaned and sterilized were
tested in the following manner. The homogenizer had 40 mL of WFI run through it once it
had been cleaned. A sample of this WFI was then tested for endotoxins with the Lonza
Limulus Amebocyte Lysate PRYOGEN-500 test kit to verify that the cleaning procedure
was successful. This process was also carried out prior to using the homogenizer to verify
no growth of any endotoxin between uses.

5.3.

Results
NMDTG was manufactured in three separate batches with reproducible

characteristics as summarized in Table 5.1. Nanoparticle size varied from 276 to 339 nm
with a narrow polydispersity index (0.20 to 0.25) and a negative zeta potential (-18.9 to 22.3 mV). MDTG concentrations in the nanosuspensions were from 111.9 to 126.6
mg/mL. DTG concentration was below the limit of detection (0.2 ng/mL). To ensure aseptic
preparation of the nanosuspensions endotoxin levels in the prepared nanoformulations
were determined. Formulation endotoxin concentrations were below 5 EU/kg.
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A single IM injection of NMDTG was administered to three rhesus macaques.
Neutrophil, lymphocyte, and monocyte counts determined prior to NMDTG administration
and weekly after administration (Fig. 5.1) were consistent. A solitary increase in neutrophil
counts was recorded at day 70 and reflected the development of an abscess near the site
of injection in a single animal which was deemed not drug-associated. Full resolution was
made by drainage and antibiotic treatment. An initial mild redness and swelling observed
at the injection site was resolved in all animals by day 7. Liver and kidney metabolic
profiles were unchanged in all animals following NMDTG treatment (Table 5.4-5.6). No
weight changes or adverse physical signs were recorded in any of the animals after
formulation injection (data not shown). Parent and prodrug concentrations in plasma and
blood leukocytes were determined following NMDTG administration. Plasma DTG
concentrations peaked at day 1 at 602 + 269 ng/mL and remained above the PA-IC90 of
64 ng/mL for 35 days (Fig. 5.2A) and above 10 ng/mL for 91 days. The extended
pharmacokinetic profile of NMDTG was demonstrated by the assessment of DTG plasma
apparent half-life (t1/2; 467 + 28 h) and mean residence time (MRT; 691.7 + 98.4 h) (Table
5.2). Plasma prodrug concentrations, although variable, remained above the limit of
detection (at or around 10 ng/mL) for 42 days. MDTG was observed in blood leukocytes
(Fig. 5.2B) through day 42, however DTG concentrations were at the limit of detection
after 14 days. The PK parameters of both MDTG and DTG in PBMCs reflected those in
plasma, especially the apparent half-lives, which indicates that the intracellular and
plasma concentrations were in equilibrium. Similar to plasma, extended apparent half-life
was observed for both MDTG (t1/2 = 542 h) and DTG (t1/2 = 460 h) in PBMCs (Table 5.3).
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5.4.

Discussion
The idea of long-acting injectable drugs for chronic treatment of disease has found

therapeutic precedent in the areas of antipsychotics and contraception [192-195]. The
development of long-acting injectables for antiretroviral drugs has great promise. This
includes, but is not limited to, the potential to improve regimen adherence, reduce drug
side-effects and development of drug resistance [73,196], and serve as a pre-exposure
prophylaxis regimen [73,187,192]. To prove practical for human use, the medicines need
to provide prophylactic prevention of HIV-1 infection when given at intervals of once
monthly or longer [72,73,187]. Our laboratories have been at the forefront of this effort by
using chemical modifications of hydrophilic and hydrophobic drugs to improve drug
hydrophobicity and lipophilicity [81,112]. Incorporation of the hydrophobic, lipophilic
derivatives into nanoformulations has produced injectable formulations of drugs that can
be administered monthly to target viral cell and tissue reservoirs and suppress HIV
infection in humanized mouse models [81,112,142]. The present data demonstrate that a
single intramuscular injection of long-acting NMDTG provides plasma drug levels above
the PA-IC90 in rhesus macaques for one month and can greatly extend drug apparent halflife. The relatively higher MDTG levels compared to DTG in PBMCs indicate that the
nanoformulation is taken into mononuclear phagocytes that can act as secondary drug
depots, as have been observed in rodent studies [111,197]. The study illustrates that these
formulations can be reproducibly and safely produced and with additional modest
modification in volume and in hydrophobicity could be ready for human clinical trial scaleups. This is a major step forward in development and production of a long-acting DTG
formulation. Additional drug and formulation modifications are in development to
effectively realize a translatable formulation that can be delivered in a clinically relevant
dose volume and provide, following a single injection, plasma drug levels at one month
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above the Ctrough level of 840 ng/mL observed in adults given a 50 mg daily oral dose of
DTG [189].
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5.5.

Figures

Figure 5. 1. White blood cell counts following NMDTG administration in rhesus
macaques.
Complete blood count (CBC) samples were collected into EDTA tubes and assessed by
manual differentiation. Data are expressed as mean + standard deviation (n = 3).
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Figure 5. 2. Pharmacokinetics in rhesus macaques.
Plasma (A) and blood leukocyte (B) DTG and MDTG concentrations following NMDTG
administration in rhesus macaques. Data are expressed as mean + standard deviation (A,
n = 3; B, n = 2 to 3). Dashed line indicates DTG PA-IC90 of 64 ng/mL.
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Tables

Table 5. 1. Physicochemical characteristics of NMDTG batches.
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Table 5. 2. PK parameters in rhesus macaques.
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Table 5. 3. PBMC PK parameters in rhesus macaques.
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Table 5. 4. Plasma metabolic panel for monkey 5009.
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Table 5. 5. Plasma metabolic panel for monkey 6039.
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Table 5. 6. Plasma metabolic panel for monkey 6049.
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CHAPTER 6 – DISCUSSION

Increased interest in ARV and viral eradication strategies birthed the development
of long acting ART nanocarriers. The emergence of LASER ART as part of any clinical
regimen provides real potential to facilitate improved therapeutic outcomes. Such drug
delivery systems for treatment and prevention of HIV-1 and other infections are of
immediate need. A number of nanomedicines are being investigated to optimize drug
pharmacokinetics and biodistribution, mitigate off target toxicity, and improve penetrance
into viral reservoirs. While progress has been made in extending the apparent half-life of
ART, the main limitations of the existing drug carriers include requirements for high
injectable doses and suspension volumes. LASER products that enable ART delivery to
anatomical reservoirs while maintaining therapeutic drug concentrations over time periods
measured in months are of immediate need. This will require carriers with appropriate
surface chemistry for cell and tissue recognitions. Current approaches to HIV elimination
are focused on designing products that are co-administered with adjunctive medicines that
boost autophagosomal depots to ensure sustained antiviral activities in HIV sanctuaries.
These advancements provide strong support of nanomedicine-based platforms for
delivery of antiretroviral drugs and can be taken with medicines that facilitate elimination
of infected cells or excise integrated proviral DNA towards establishing a viral cure.
A key part of any effective antiretroviral regimen rests in ensuring that patients take
their prescribed medicines [50,198]. HIV/AIDS treatment regimens are currently defined
by daily or twice-daily dosing intervals [199]. Adherence underlies clinical responsiveness
and any consequent emergence of viral resistance. It also affects the accompanying
stability of CD4+ T cell numbers and function [154]. Thus, any ART regimens that allow
infrequent dosing with an ability to maintain consistent drug levels in plasma and tissues
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sufficiently above the IC90 would improve clinical outcomes and hold viral replication in
check [155,156]. Particle size and physicochemical properties were used to optimize
release of drug molecules from delivery systems. Nanoparticle based systems are readily
taken up by cells and disseminated into tissues to form drug depots at these sites for
subsequent slow release [200]. Other controlled release injection site drug depot
formulations include microparticle carrier systems [201,202]. However, microparticles tend
to aggregate limiting their usage due to lack of particle homogeneity, leading to injection
site reactions [203].
Long-acting drug formulations have been extensively investigated, including their
prolonged apparent half-life, high protein-binding, lipid or surfactant drug nanocrystal
encasement, rapid drug entry into monocyte-macrophages, and slow drug release
[184]. These long-acting properties are mostly due to enhanced particle/drug stability,
rapid cell and barrier penetration, and/or slowed intracellular drug hydrolysis [165].
Cumulatively, these properties enhance therapeutic responses, allow for cell-mediated
drug delivery, and enable improved delivery of drugs to areas of poor drug penetrance
and viral reservoirs [122]. One of the most important of these is uptake and sequestration
into MDM. Highly mobile MDM have large storage capacities and can act as Trojan Horses
for drug delivery to circulating and tissue CD4+ T cells and viral reservoirs [109]. This is
especially operative when describing lymphoid organs, where macrophages and T cells
are in intimate contact, permitting passage of drug to such major reservoirs of HIV infection
[197,204]. Here, it is demonstrated that drug released from NMDTG-treated MDM can act
upon T cells and significantly inhibit and prevent spreading of viral infection within T cell
cultures. Macrophages can protect drugs from metabolism—prolonging apparent halflife—and enhance efficacy, PK, and biodistribution of the drug delivery system
[111,205],[206]. Once inside the macrophage, drug particles can be stored in late- and
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recycling-endosomes as well as autophagosomes and as such, create a secondary drug
depot within the tissue macrophage independent of the muscle site of injection
[113,142,207]. Indeed—and in addition to the macrophage’s phagocytic, clearance,
antigen presentation, and secretory functions—the cells also serve as viral sanctuaries,
vehicles for viral transport, and as reservoirs for HIV-1 replication [169,208]. Thus, delivery
of drug to macrophages can serve multiple critical purposes.
In clinical settings, DTG rarely elicits viral resistance mutations in infected patients
when used as first-line therapy, with suboptimal adherence driving these few mutations
[209]. In vitro, the most common mutation against DTG is the R263K that severely reduces
viral replication fitness, reducing the impact and rendering it insignificant for HIV/AIDS
treatments [210]. Prevention of renewed viral infection emerging from tissue reservoirs
experiencing suboptimal drug levels may allow infected cells to die off through normal cell
turnover without spreading virus to other cells that may act as viral reservoirs [186]. Thus,
the changes in antiretroviral drug treatment made here could limit viral replication in its
native reservoirs, allowing antiretroviral drugs alone to keep the virus in check and
attenuate new infections. The offering of sustained high plasma and tissue drug levels in
time periods measured in months, without notable drug peaks and troughs, could also
enable more efficient excision of integrated proviral DNA through CRISPR/Cas9
technologies [73]. Currently under evaluation for clinical use are transdermal patches and
ARV implants. Such devices, including dapivirine vaginal rings, subdermal silicone
tenofovir alafenamide and polymeric EFdA, are being developed for PrEP [211-213].
Refillable channel devices capable of loading multiple drugs have also been described
[214]. These devices could be loaded with NMDTG and/or other LASER ART nanocrystals
to further extend the apparent half-lives of the parent medicines with a single implant.
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LASER ART-loaded microneedle patches similar to those used to deliver injectable
contraceptives could also be used to alleviate pain during administration [215].
The concept of long-acting injectable drugs is well received by patients with HIV,
with 73% indicating that they would definitely or probably try them [216]. This number goes
up to 84% when patients were asked about monthly dosing as opposed to weekly or
biweekly dosing. Conceivably, bimonthly or longer dosing intervals would be even more
attractive. Future endeavors to further extend drug apparent half-lives and better target
macrophages, including further drug modifications, linking two drug molecules to a single
linker, combining divergent classes of antiretroviral drugs, and nanoparticle surface
decorations will shape the future of long-acting antiretroviral therapy. Future works will
focus on refinements in drug modification and formulation, and the packaging of multiple
drugs into a single formulation for delivery. Strategies such as these will further improve
adherence to drug regimens and biodistribution profiles, and maintain high drug levels for
even longer periods of time, limiting viral resistance mutations and, overall, improving ART
efficacy and patient outcomes [217-219].
The persistence of HIV-1 in its anatomical tissue sanctuaries represents a major
challenge to final viral eradication. New agents have been developed and designed to
eliminate infected cells, induce effective immune antiretroviral responses, excise latent
integrated proviral DNA, offer decoys to the viral receptor or better bring drugs to reservoir
sites by prodrug modification and encapsulation in targeted particles. These can be seen
through currently licensed products or others that have been overlooked by compositions
thought not relevant for prior use. Combined therapies that target various stages of the
virus life cycle and bring the drug to action sites with particular properties are being sought.
Such discovery efforts, I envision, will result in new targets to combat latent or restricted
viral infections. To date, there are few commercial slow release products of antiretroviral

109
therapies, in part due to inherent poor physicochemical properties of the drug compounds.
With the advent of promising anti-HIV compounds, molecules that induce autophagy,
latency reversing agents and gene therapy strategies, it is time to invest in the
development of slow release products that would bring us closer to a functional cure. Slow
release products have the potential to enable delivery of ART with inherent poor
physiochemical properties. Carriers with high drug loading capacities, extended circulation
times and active targeting capabilities hold promise to improve the delivery of currently
licensed short acting ART, enhance drug dissolution rates and improve bioavailability,
protect drugs from rapid clearance through metabolism, and localize therapeutic
concentrations of ART at intracellular and tissue sites of infection. The next generation of
ART slow release products will also be characterized by infrequent parenteral
administration. This will enable reductions in toxicities, viral loads and resistance patterns
while improving drug regimen adherence. Such advances hold great potential to
accelerate viral clearance in infectious reservoirs that include GALT, lymph nodes, the
genitourinary tract, and the CNS. Innovative approaches to bridge bench to bedside
development of ART slow release products and other strategies to eradicate HIV-1
reservoirs will require collaboration across academia, industry and healthcare providers.
Current and future directions for the creation of a long-acting DTG involve the
development of a library of various DTG prodrugs (Fig 6.1). Several DTG prodrugs have
already been synthesized and are currently under evaluation. New DTG prodrugs involve
combinations of changes in the carbon chain length of the attached fatty-acid pro-moiety,
different linkages of the fatty-acid pro-moiety to the parent drug, and attachment of two
DTG molecules to a single linker. By modifying DTG with aliphatic fatty pro-moieties of
varying lengths it can allow the fine tuning of cleavage kinetics and chemical properties to
meet our specific needs. Rapid cleavage kinetics are not desired, as it would elicit burst

110
drug release and possible toxicity. Conversely, a lack of adequate conversion would limit
the amount of active compound that is delivered. Similar tuning can be achieved through
the use of different linkages of the fatty-acid pro-moiety to the parent drug. Ester bonds
are typical of many prodrugs currently in clinical use, however, carbonate ester bonds are
more stable than normal ester bonds but only when both alcohol groups are esterified.
Linkers between the pro-moiety and parent drug may also sterically hinder cleavage of the
prodrug, slowing release of the active pharmaceutical agent. Finally, connecting two DTG
molecules to a single linker may allow for great reductions in the volume needed for
injection; one of the principle challenges of current long-acting formulations under clinical
development for HIV-1 treatment and prevention. Therefore, synthesizing highly
hydrophobic DTG prodrugs designed with slow, controlled, cleavage kinetics will yield
sustained plasma concentrations beyond current capabilities and oral therapy.
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6.1.

Figures

Figure 6. 1. Synthesized DTG prodrug library of structures for future
characterization and testing.
(a) Parent DTG. (b) Fourteen-carbon fatty-acid ester modified DTG prodrug. (c) Eighteencarbon fatty-acid ester modified DTG prodrug. (d) Twenty-two carbon fatty-acid ester
modified DTG prodrug. (e) Docosahexaenoic acid (DHA) omega-3 fatty-acid ester
modified DTG prodrug. (f) Twenty-two carbon fatty-acid carbonate ester modified DTG
prodrug. (g) Twenty-two carbon fatty-acid with four-carbon linker modified DTG prodrug.
(h) Eighteen-carbon fatty-acid ester modified DiDTG prodrug. (i) Sixteen-carbon fatty-acid
with proline linker modified DTG prodrug. (j) Nine-carbon fatty-acid ester modified DiDTG
prodrug.
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